

# Syntheses, Structures, and Reactivity of New Pentamethylcyclopentadienyl-Rhodium(III) and -iridium(III) 4-Acyl-5-Pyrazolonate Complexes

Claudio Pettinari,<sup>\*,§</sup> Riccardo Pettinari,<sup>§</sup> Mauro Fianchini,<sup>§</sup> Fabio Marchetti,<sup>§</sup> Brian W. Skelton,<sup>‡</sup> and Allan H. White<sup>‡</sup>

Department of Chemical Sciences, University of Camerino, Via S. Agostino 1, 62032 Camerino, Italy, and Chemistry M313, School of Biomolecular, Biomedical and Chemical Sciences, University of Western Australia, Crawley, Western Australia, 6009, Australia

Received June 16, 2005

New [Cp\*M(Q)CI] complexes (M = Rh or Ir, Cp\* = pentamethylcyclopentadienyl, HQ = 1-phenyl-3-methyl-4R(C=O)-pyrazol-5-one in general, in detail HQ<sup>Me</sup>, R = CH<sub>3</sub>; HQ<sup>Et</sup>, R = CH<sub>2</sub>CH<sub>3</sub>; HQ<sup>Piv</sup>, R = CH<sub>2</sub>--C(CH<sub>3</sub>)<sub>3</sub>; HQ<sup>Bn</sup>, R = CH<sub>2</sub>--(C<sub>6</sub>H<sub>5</sub>); HQ<sup>S</sup>, R = CH--(C<sub>6</sub>H<sub>5</sub>)<sub>2</sub>) have been synthesized from the reaction of [Cp\*MCl<sub>2</sub>]<sub>2</sub> with the sodium salt, NaQ, of the appropriate HQ proligand. Crystal structure determinations for a representative selection of these [Cp\*M(Q)CI] compounds show a pseudo-octahedral metal environment with the Q ligand bonded in the *O*,*O*-chelating form. In each case, two enantiomers (*S*<sub>M</sub>) and (*R*<sub>M</sub>) arise, differing only in the metal chirality. The reaction of [Cp\*Rh(Q<sup>Bn</sup>)CI] with MgCH<sub>3</sub>Br produces only halide exchange with the formation of [Cp\*Rh(Q<sup>Bn</sup>)Br]. The [Cp\*Rh(Q)CI] complexes react with PPh<sub>3</sub> in dichloromethane yielding the adducts Cp\*Rh(Q)Cl/PPh<sub>3</sub> (1:1) which exist in solution in two different isomeric forms. The interaction of [Cp\*Rh(Q<sup>Me</sup>)CI] with AgNO<sub>3</sub> in MeCN allows generation of [Cp\*Rh(Q<sup>Me</sup>)(MeCN)]NO<sub>3</sub>•3H<sub>2</sub>O, whereas the reaction of [Cp\*Rh(Q<sup>Me</sup>)CI] with AgClO<sub>4</sub> in the same solvent yields both [Cp\*Rh(Q<sup>Me</sup>)(H<sub>2</sub>O)]ClO<sub>4</sub> and [Cp\*Rh(Cl)(H<sub>2</sub>O)<sub>2</sub>]ClO<sub>4</sub>; the H<sub>2</sub>O molecules derive from the notrigorously anhydrous solvents or silver salts.

### Introduction

The chemistry of Rh(I)  $\beta$ -diketonates has been extensively investigated and a number of complexes of the form [Rh( $\beta$ diketonate)(L)<sub>2</sub>] (where L = alkene, CO, P(aryl)<sub>3</sub>, and P(alkyl)<sub>3</sub>) have found applications in a variety of reactions including, for example, alkene hydroboration,<sup>1</sup> CO hydrogenation,<sup>2</sup> and hydroformylation.<sup>3</sup> [Rh(acac)(CO)<sub>2</sub>] is a known catalytic system in the presence of tertiary phosphines for hydroformylation, hydrogenation, and isomerization reactions of olefins.<sup>4</sup> By contrast, only a limited number of Rh(III)  $\beta$ -diketonate complexes, containing the pentamethylcyclopentadienyl ligand (Cp\*), have been synthesized,

10.1021/ic050985r CCC: \$30.25 © 2005 American Chemical Society Published on Web 09/27/2005

and of these, only the dinuclear cationic compound  $[Rh_2(\eta^5-Cp^*)_2(acac)_2][BF_4]_2$  has been structurally characterized.<sup>5</sup> Optically active half-sandwich metallocene complexes of rhodium(III) and iridium(III) have recently attracted considerable attention because of their ability to act as active stereospecific catalysts.<sup>6</sup> Other Cp\*M compounds, such as the cationic iridium complex,  $[Cp*IrMe(PMe_3)-(ClCH_2Cl)]^+[BAr_4]^-$  (Ar = aryl), exhibit highly interesting reactivity in the C–H activation reactions of various functionalized substrates at ambient temperature.<sup>7</sup> A number of complexes containing N^N<sup>8</sup> and N^O<sup>9</sup> bidentate ligands have been described and employed for enantioselective hydrogen transfer reactions.<sup>10</sup> Most of the organometallic chiral-at-metal compounds are half-sandwich complexes containing a Cp\*, a halide ligand, and an unsymmetrical

(7) Arndtsen, B. A.; Bergman, R. G. Science 1995, 20, 1970-1973.

Inorganic Chemistry, Vol. 44, No. 22, 2005 7933

<sup>\*</sup> To whom correspondence should be addressed. Fax: 0039 0737 637345. E-mail: claudio.pettinari@unicam.it.

<sup>&</sup>lt;sup>§</sup> University of Camerino.

<sup>&</sup>lt;sup>‡</sup> University of Western Australia.

 <sup>(</sup>a) Westcott, S. A.; Blom, H. P.; Marder, T. B.; Baker, R. T. J. Am. Chem. Soc. 1992, 114, 8863–8869. (b) Westcott, S. A.; Marder, T. B.; Baker, R. T. Organometallics 1993, 12, 975–979.

<sup>(2)</sup> Baker, R. T.; Nguyen, P.; Marder, T. B.; Westcott, S. A. Angew. Chem., Int. Ed. Engl. 1995, 34, 1336–1338.

<sup>(3)</sup> Angermund, K.; Baumann, W.; Donius, E.; Fornika, R.; Görls, H.; Kessler, M.; Krüger, C.; Leitner, W.; Lutz, F. Chem.-Eur. J. 1997, 3, 755-764.

 <sup>(4) (</sup>a) Moasser, B.; Gladfelter, W. L.; Roe, D. C. Organometallics 1995, 14, 3832–3838. (b) Trzeciak, A. M.; Glowiak, T.; Grzybek, R.; Ziolkowski, J. J. J. Chem. Soc., Dalton Trans. 1997, 11, 1831–1837.

<sup>(5)</sup> Rigby, W.; Lee, H. B.; Bailey, P. M.; McCleverty, J.; Maitlis, P. M. J. Chem. Soc., Dalton Trans. 1979, 387–394.

<sup>(6)</sup> Hamada, T.; Torii, T.; Izawa, K.; Noyori, R.; Ikariya, T. Org. Lett. 2002, 4, 4373-4376.



Figure 1. 4-Acyl-5-pyrazolone (HQ) pro-ligands employed in this work.

anionic chelate ligand with a chiral carbon atom. This type of system has been thoroughly investigated and has been reported to yield two diastereomers differing in the metal configuration. As the configuration at the metal is often labile, epimerization processes have been observed in solution.<sup>11</sup> Analogous chemistry with related O,O-donors has received less attention, one reason being that Rh–O and Ir–O linkages are considered to be characteristically weak because of a mismatch of the hard basic ligands with the soft late-transition-metal centers.

4-Acyl-5-pyrazolones (HQ) (Figure 1) have often been described as analogues of  $\beta$ -diketone ligands and employed in their anionic chelating  $\sigma$ -donor forms in complexes of different metal acceptors.<sup>12</sup> They can be easily functionalized in the acyl fragment, and their complexes are generally more stable than the corresponding  $\beta$ -diketonates.

We have previously reported that the acylpyrazolonates are suitable ligands for the synthesis of stable Rh(I) metal complexes, which have been widely investigated by X-ray crystallography and NMR spectroscopy.<sup>13</sup> As an extension of the previous investigations on compounds that contain the { $(\eta^{5}-Cp^{*})M$ } fragments (M = Rh, Ir),<sup>14</sup> we report, here, a systematic study of the reactions of [{ $(\eta^{5}-Cp^{*})MCl$ }<sub>2</sub>( $\mu$ -Cl)<sub>2</sub>] (M = Rh, Ir) compounds with HQ ligands (Figure 1). The reactivities of some of these derivatives toward Grignard reagents, PPh<sub>3</sub> and AgX (X = NO<sub>3</sub> or ClO<sub>4</sub>) are also included.

# **Experimental Section**

**Materials and Methods.** All chemicals and reagents were of reagent grade quality and were used as received without further purification. All solvents were distilled prior to use. Toluene and light petroleum (40-60 °C) were dried by refluxing over freshly cut sodium. Methanol was dried over CaO. Dichloromethane was freshly distilled from CaH<sub>2</sub>. Other solvents were dried and purified by standard procedures. The samples were dried in vacuo to constant weight (20 °C,  $\sim$  0.1 Torr). Elemental analyses were carried out in-house with a Fisons Instruments 1108 CHNSO-elemental analyzer. IR spectra in the range of  $4000-150 \text{ cm}^{-1}$  were recorded with a Perkin-Elmer System 2000 FT-IR instrument. <sup>1</sup>H, <sup>13</sup>C{<sup>1</sup>H}, and <sup>31</sup>P{<sup>1</sup>H} NMR spectra were recorded on a VXR-300 Varian Spectrometer (300 MHz for <sup>1</sup>H, 75 MHz for <sup>13</sup>C, and 121.4 MHz for <sup>31</sup>P). Melting points are uncorrected and were measured on an SMP3 Stuart scientific instrument and on a capillary apparatus. Positive and negative electrospray mass spectra were obtained with a Series 1100 MSI detector HP spectrometer, using an acetonitrile mobile phase. Solutions (3 mg/mL) for electrospray-ionization mass spectrometry (ESI-MS) were prepared using reagent-grade acetone or acetonitrile. For the ESI-MS data, masses and intensities were compared to those calculated using the IsoPro Isotopic Abundance Simulator Version 2.1.15

Syntheses of Complexes. [Chloro(pentamethylcyclopentadienyl)(1-phenyl-3-methyl-4-acetylpyrazolon-5-ato)rhodium(III)], [Cp\*Rh(O<sup>Me</sup>)Cl] (1). A toluene solution (10 mL) containing [Cp\*RhCl<sub>2</sub>]<sub>2</sub> (0.200 g, 0.32 mmol) and NaQ<sup>Me</sup> (0.157 g, 0.64 mmol) was stirred overnight under N2 at room temperature to give a redorange precipitate, which was filtered off and washed with 5 mL of toluene. The orange-brown residue was recrystallized from 1:1  $CH_2Cl_2$ /light petroleum (40-60 °C) and shown to be compound 1 (0.190 g, 0.38 mmol, 60% yield). mp: 255-258 °C. Anal. Calcd for C<sub>22</sub>H<sub>26</sub>ClN<sub>2</sub>O<sub>2</sub>Rh: C, 54.06; H, 5.36; N, 5.73. Found: C, 53.73; H, 5.45; N, 5.45. IR (Nujol, cm<sup>-1</sup>): 1606s, 1590s, 1575s, 1539s, v(C…C, C…N), 514m, 456s, 445sh, 398m, 301w, 259s v(Rh-Cl).<sup>1</sup>H NMR (CDCl<sub>3</sub>, 293 K):  $\delta$  1.67 (s, 15H, CH<sub>3Cp\*</sub>), 2.35 (s, 3H, 3-CH<sub>3</sub>), 2.44 (s, 3H, COCH<sub>3</sub>), 7.15-7.40m, 7.97d (5H, N-C<sub>6</sub> $H_5$ ). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 293 K):  $\delta$  8.96 (s,  $CH_{3Cp*}$ ), 17.65 (s, 3-CH<sub>3</sub>), 28.22 (COCH<sub>3</sub>), 92.30, 92.49 (d,  $C_{Cp*}$ ,  $J(^{103}Rh^{-13}C) =$ 9.5 Hz), 105.80 (s, C4), 120.88, 124.94, 128.59, 139.18 (s, N-C<sub>6</sub>H<sub>5</sub> of Q), 148.90 (s, C3), 162.57 (s, C5), 190.26 (s, CO).

[Chloro(pentamethylcyclopentadienyl)(1-phenyl-3-methyl-4acetylpyrazolon-5-ato)iridium(III)], [Cp\*Ir(QMe)Cl] (2). A toluene solution (10 mL) containing [Cp\*IrCl<sub>2</sub>]<sub>2</sub> (0.201 g, 0.25 mmol) and NaQMe (0.132 g, 0.55 mmol) was stirred overnight under N2 at room temperature to give an orange precipitate, which was filtered off and washed with 5 mL of toluene. The residue was recrystallized from 1:1 CH<sub>2</sub>Cl<sub>2</sub>/light petroleum (40-60 °C) and shown to be compound 2 (0.161 g, 0.28 mmol, 55% yield). mp: 278-280 °C. Anal. Calcd for C<sub>22</sub>H<sub>26</sub>ClIrN<sub>2</sub>O<sub>2</sub>: C, 45.71; H, 4.53; N, 4.85. Found: C, 45.24; H, 4.85; N, 4.83. IR (Nujol, cm<sup>-1</sup>): 1602s, 1590s, 1575s, 1539s, v(C…C, C…N), 513w, 466m, 455w, 270s v(Ir-Cl).<sup>1</sup>H NMR (CDCl<sub>3</sub>, 293 K): δ 1.64 (s, 15H, CH<sub>3Cp\*</sub>), 2.37 (s, 3H, 3-CH<sub>3</sub>), 2.41 (s, 3H, COCH<sub>3</sub>), 7.17–7.43m, 7.85d, 7.95d (5H, N-C<sub>6</sub>H<sub>5</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 293 K): δ 9.13 (s, CH<sub>3Cp\*</sub>), 17.47 (s, 3-CH<sub>3</sub>), 27.68 (COCH<sub>3</sub>), 83.57 (s, C<sub>Cp\*</sub>), 106.61 (s, C4), 120.90, 125.19, 128.67, 138.98 (s, N-C<sub>6</sub>H<sub>5</sub>), 148.94 (s, C3), 161. 16 (s, C5), 189.22 (s, CO).

[Chloro(pentamethylcyclopentadienyl)(1-phenyl-3-methyl-4propionylpyrazolon-5-ato)rhodium(III)], [Cp\*Rh(Q<sup>Et</sup>)Cl] (3). Orange compound 3 (0.090 g, 0.17 mmol, 64% yield) was prepared following a procedure similar to that reported for 1 using

<sup>(8) (</sup>a) Murata, K.; Ikariya, T.; Noyori, R. J. Org. Chem. 1999, 64, 2186–2187. (b) Carmona, D.; Lahoz, F. J.; Felipe, S.; Oro, L.; Lamata, M. P.; Viguri, F.; Mir, C.; Cativiela, C.; Lopez-ram de Viu, M. P. Organometallics 1998, 17, 2986–2995.

<sup>(9) (</sup>a) Carmona, D.; Vega, C.; Lahoz, F. J.; Atencio, R.; Oro, L. A.; Lamata, M. P.; Viguri, F.; San Josè, E. *Organometallics* 2000, 19, 2273–2280. (b) Carmona, D.; Vega, C.; Lahoz, F. J.; Atencio, R.; Oro, L. A.; Lamata, M. P.; Viguri, F.; San Josè, E.; Vega, C.; Reyes, J.; Joò, F.; Katho, A. *Chem.–Eur. J.* 1999, 5, 1544–1564.

<sup>(10)</sup> Carmona, D.; Lamata, M. P.; Oro, L. A. Eur. J. Inorg. Chem. 2002, 2239–2251.

<sup>(11)</sup> Brunner, H.; Kollnberger, A.; Zabel, M. Polyhedron, 2003, 22, 2639– 2646.

<sup>(12) (</sup>a) Marchetti, F.; Pettinari, C.; Cingolani, A.; Leonesi, D.; Drozdov, A.; Troyanov, S. I. J. Chem. Soc., Dalton Trans. 1998, 3325-3334.
(b) Caruso, F.; Rossi, M.; Tanski, J.; Sartori, R.; Sariego, R.; Moya, S.; Diez, S.; Navarrete, E.; Cingolani, A.; Marchetti, F.; Pettinari, C. J. Med. Chem. 2000, 43, 3665-3670. (c) Cingolani, A.; Effendy; Marchetti, F.; Pettinari, C.; Pettinari, R.; Skelton, B. W.; White, A. H. Inorg. Chem. 2002, 41, 1151-1161.

<sup>(13) (</sup>a) Pettinari, C.; Accorroni, F.; Cingolani, A.; Marchetti, F.; Cassetta, A.; Barba, L. J. Organomet. Chem. 1998, 566, 187–201. (b) Pettinari, C.; Marchetti, F.; Pettinari, R.; Pizzabiocca, A.; Drozdov, A.; Troyanov, S. I.; Vertlib, V. J. Organomet. Chem. 2003, 688, 216–226.

<sup>(14)</sup> Carmona, E.; Cingolani, A.; Marchetti, F.; Pettinari, C.; Pettinari, R.; Skelton, B. W.; White, A. H. Organometallics 2003, 22, 2820–2826.

<sup>(15)</sup> Senko, M. W. IsoPro Isotopic Abundance Simulator, version 2.1; National High Magnetic Field Laboratory, Los Alamos National Laboratory: Los Alamos, NM.

### Rhodium(III) Cyclopentadienyl β-diketonate Complexes

[Cp\*RhCl<sub>2</sub>]<sub>2</sub> and NaQ<sup>Et</sup> and was recrystallized from 1:1 CH<sub>2</sub>Cl<sub>2</sub>/ light petroleum (40–60 °C). mp 217–219 °C. Anal. Calcd for C<sub>23</sub>H<sub>28</sub>ClN<sub>2</sub>O<sub>2</sub>Rh: C, 54.94; H, 5.61; N, 5.57. Found: C, 54.90; H, 5.84; N, 5.20. IR (Nujol, cm<sup>-1</sup>): 1605s, 1589s, 1576s, 1534s,  $\nu$ (C···C, C···N), 461m, 270s  $\nu$ (Rh–Cl).<sup>1</sup>H NMR (CDCl<sub>3</sub>, 293K):  $\delta$  1.24 (t, 3H, CH<sub>2</sub>CH<sub>3</sub>), 1.67 (s, 15H, CH<sub>3Cp\*</sub>), 2.35 (s, 3H, 3-CH<sub>3</sub>), 2.59 (dd, <sup>2</sup>J(A–X) = 7.32 Hz,  $\Delta\delta\nu/J$  = 2.04), 2.66 (dd, <sup>2</sup>J(A–X) = 7.32 Hz,  $\Delta\delta\nu/J$  = 1.93), 2.80 (dd, <sup>2</sup>J(A–X) = 7.32 Hz,  $\Delta\delta\nu/J$ = 2.00), 2.88 (dd, <sup>2</sup>J(A–X) = 7.32 Hz,  $\Delta\delta\nu/J$  = 2.00), 7.12– 7.20m, 7.32–7.40m, 7.95d (5H, N–C<sub>6</sub>H<sub>5</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 293 K):  $\delta$  8.92 (s, CH<sub>3Cp\*</sub>), 9.84 (s, CH<sub>2</sub>CH<sub>3</sub>), 17.76 (s, 3-CH<sub>3</sub>), 32.14 (s, CH<sub>2</sub>CH<sub>3</sub>), 92.19, 92.38 (d, C<sub>Cp\*</sub>, J(<sup>103</sup>Rh–<sup>13</sup>C) = 9.4 Hz), 105.80 (s, *C4*), 120.88, 124.86, 128.56, 139.26 (s, N–C<sub>6</sub>H<sub>5</sub>), 148.44 (s, *C3*), 162.80 (s, *C5*), 193.80 (s, *CO*).

[Chloro(pentamethylcyclopentadienyl)(1-phenyl-3-methyl-4-(3, 3-dimethyl but an oyl) pyrazolon-5-ato) rhodium (III)], [Cp\*Rh-10, Cp\*Rh-10, Cp\*(Q<sup>Piv</sup>)Cl] (4). Dark yellow compound 4 (0.092 g, 0.17 mmol, 63% yield) was prepared following a procedure similar to that reported for 1 using [Cp\*RhCl<sub>2</sub>]<sub>2</sub> and NaQ<sup>Piv</sup> and was recrystallized from 1:1 CH<sub>2</sub>Cl<sub>2</sub>/light petroleum (40-60 °C). mp: 235-238 °C. Anal. Calcd for C<sub>26</sub>H<sub>34</sub>ClN<sub>2</sub>O<sub>2</sub>Rh: C, 57.31; H, 6.29; N, 5.14. Found: C, 56.93; H, 6.31; N, 5.03. IR (Nujol, cm<sup>-1</sup>): 1606s, 1591s, 1578s, 1537s v(C…C, C…N), 510m, 472s, 266s v(Rh-Cl). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 293 K):  $\delta$  1.12 (s, 9H, CH<sub>2</sub>C(CH<sub>3</sub>)<sub>3</sub>), 1.71 (s, 15H,  $CH_{3Cp^*}$ ), 2.39 (s, 3H, 3- $CH_3$ ), 2.49, 2.55, 2.68, 2.74 (q, 2H<sub>gem</sub>),  $CH_2C(CH_3)_3$ ,  ${}^2J(A-X) = 13.18$  Hz,  $\Delta\delta v/J = 2.88$ ), 7.16–7.41m, 7.95d (5H, N-C<sub>6</sub> $H_5$ ). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 293 K):  $\delta$  8.90 (s, CH<sub>3Cp\*</sub>), 18.25 (s, 3-CH<sub>3</sub>), 30.43 (s, CH<sub>2</sub>C(CH<sub>3</sub>)<sub>3</sub>), 32.55 (s, CH<sub>2</sub>C(CH<sub>3</sub>)<sub>3</sub>), 50.09 (s, CH<sub>2</sub>C(CH<sub>3</sub>)<sub>3</sub>), 91.99, 92.13 (d, C<sub>Cp\*</sub>,  $J(^{103}\text{Rh}-^{13}\text{C}) = 9.2$  Hz), 120.73, 124.66, 128.28, 138.99 (s, N-C<sub>6</sub>*H*<sub>5</sub>), 148.19 (s, *C3*), 192.84 (s, *CO*), *C*4 and *C*5 not observed.

[Chloro(pentamethylcyclopentadienyl)(1-phenyl-3-methyl-4-(3,3-dimethylbutanoyl)pyrazolon-5-ato)iridium(III)], [Cp\*Ir-(QPiv)Cl] (5). Yellow compound 5 (0.105 g, 0.16 mmol, 58% yield) was prepared following a procedure similar to that reported for 3 using [IrCp\*Cl<sub>2</sub>]<sub>2</sub> and NaQ<sup>Piv</sup> and was recrystallized from 1:1 CH<sub>2</sub>Cl<sub>2</sub>/light petroleum (40-60 °C). mp: 160-162 °C. Anal. Calcd for C<sub>26</sub>H<sub>34</sub>ClIrN<sub>2</sub>O<sub>2</sub>: C, 49.24; H, 5.40; N, 4.42. Found: C, 49.07; H, 5.35; N, 4.20. IR (Nujol, cm<sup>-1</sup>): 1603s, 1591s, 1578s, 1537m v(C.-C, C.-N), 510w, 476w, 279s v(Ir-Cl). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 293 K): δ 1.11 (s, 9H, CH<sub>2</sub>C(CH<sub>3</sub>)<sub>3</sub>), 1.66 (s, 15H, CH<sub>3Cp\*</sub>), 2.41  $(s, 3H, 3-CH_3), 2.46, 2.53, 2.67, 2.74 (q, 2H_{gem}, CH_2C(CH_3)_3, {}^2J(A-$ X) = 13.19 Hz,  $\Delta \delta v/J$  = 3.20), 7.15–7.41m, 7.91d (5H, N–C<sub>6</sub>H<sub>5</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 293 K): δ 9.32 (s, CH<sub>3Cp\*</sub>), 18.33 (s, 3-CH<sub>3</sub>), 30.63 (s, CH<sub>2</sub>C(CH<sub>3</sub>)<sub>3</sub>), 32.65 (s, CH<sub>2</sub>C(CH<sub>3</sub>)<sub>3</sub>), 49.96 (s, CH<sub>2</sub>C-(CH<sub>3</sub>)<sub>3</sub>), 83.48 (s, C<sub>Cp\*</sub>), 108.13 (s, C4), 120.94, 125.14, 128.62, 138.04 (s, N-C<sub>6</sub>H<sub>5</sub>). 148.52 (s, C3), 161. 86 (s, C5), 192.24 (s, CO).

[Chloro(pentamethylcyclopentadienyl)(1-phenyl-3-methyl-4-(2-phenylacetyl)pyrazolon-5-ato)rhodium(III)], [Cp\*Rh(Q<sup>Bn</sup>)-Cl] (6). Brown-red compound 6 (0.110 g, 0.19 mmol, 59% yield) was prepared following a procedure similar to that reported for 1 using [Cp\*RhCl<sub>2</sub>]<sub>2</sub> and NaQ<sup>Bn</sup> and was recrystallized from 1:1 CH<sub>2</sub>-Cl<sub>2</sub>/light petroleum (40–60 °C). mp: 230–233 °C. Anal. Calcd for C<sub>28</sub>H<sub>30</sub>ClN<sub>2</sub>O<sub>2</sub>Rh: C, 59.53; H, 5.35; N, 4.96. Found: C, 59.53; H, 5.61; N, 4.95. IR (Nujol, cm<sup>-1</sup>): 1607s, 1590s, 1577s, 1531s  $\nu$ (C···C, C, C···N), 512w, 456s, 264s  $\nu$ (Rh–Cl). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 293K): δ 1.48 (s, 15H, CH<sub>3Cp\*</sub>), 2.43 (s, 3H, 3-CH<sub>3</sub>), 3.79, 3.87, 4.23, 4.31 (q, 2H<sub>gem</sub>, COCH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>, <sup>2</sup>J(A–X) = 15.40 Hz, Δδ $\nu$ /J = 5.81), 7.12–7.40, 7.94–7.99 (m, 10H, Ph). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 318 K): δ 1.48 (s, 15H, CH<sub>3Cp\*</sub>), 2.41 (s, 3H, 3-CH<sub>3</sub>), 3.81, 3.86, 4.22, 4.26 (q, 2H<sub>gem</sub>, CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>, <sup>2</sup>J(A–X) = 14.90 Hz, Δδ $\nu$ /J = 8.18), 7.12–7.40m, 7.96d (10H, N–C<sub>6</sub>H<sub>5</sub> and COCH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 293 K):  $\delta$  8.65 (s,  $CH_{3Cp^*}$ ), 17.74 (s, 3- $CH_3$ ), 44.86 (s,  $CH_2C_6H_5$ ), 92.25, 92.44 (d,  $C_{Cp^*}$ ,  $J(^{103}Rh-^{13}C) = 9.5$  Hz), 120.86, 124.98, 126.80, 128.54, 128.58, 129.83, 136.38, 139.14 (s,  $N-C_6H_5$  and COCH<sub>2</sub> $C_6H_5$ ), 148.34 (s, C3), 189.98 (s, CO),  $C_4$  and  $C_5$  not observed.

[Chloro(pentamethylcyclopentadienyl)(1-phenyl-3-methyl-4-(2-phenylacetyl)pyrazolon-5-ato)iridium(III)], [Cp\*Ir(Q<sup>Bn</sup>)Cl] (7). Dark-yellow compound 7 (0.075 g, 0.15 mmol, 55% yield) was prepared following a procedure similar to that reported for 3 using [Cp\*IrCl<sub>2</sub>]<sub>2</sub> and NaQ<sup>Bn</sup> and was recrystallized from 1:1 CH<sub>2</sub>-Cl<sub>2</sub>/light petroleum (40-60 °C). mp: 180-185 °C. Anal. Calcd for C<sub>28</sub>H<sub>30</sub>ClIrN<sub>2</sub>O<sub>2</sub>: C, 51.41; H, 4.62; N, 4.28. Found: C, 51.20; H, 4.70; N, 4.10. IR (Nujol, cm<sup>-1</sup>): 1605s, 1590m, 1577s, 1532m  $\nu$ (C···-C, C···-N), 512m, 462w, 273s  $\nu$ (Ir–Cl). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 293 K): δ 1.47 (s, 15H, CH<sub>3Cp\*</sub>), 2.44 (s, 3H, 3-CH<sub>3</sub>), 3.77, 3.84, 4.22, 4.30 (q, 2H<sub>gem</sub>, COCH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>,  ${}^{2}J(A-X) = 15.20$  Hz,  $\Delta \delta v/J$ = 6.02), 7.18–7.41m, 7.93d (10H, N–C<sub>6</sub>H<sub>5</sub> and COCH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 293 K): δ 8.88 (s, CH<sub>3Cp\*</sub>), 17.58 (s, 3-CH<sub>3</sub>), 44.57 (s, CH<sub>2</sub>(Ph)), 83.56 (s, C<sub>Cp\*</sub>), 106.66 (s, C4), 120.86, 125.23, 126.89, 128.60, 128.67, 129.67, 135.85, 138.91 (s,  $N-C_6H_5$  and COCH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>), 148.41 (s, C3), 161.61 (s, C5), 188.83 (s, CO).

[Chloro(pentamethylcyclopentadienyl)(1-phenyl-3-methyl-4-(2,2-diphenylacetyl)pyrazolon-5-ato)rhodium(III)], [Cp\*Rh-(Q<sup>S</sup>)Cl] (8). Orange compound 8 (0.101 g, 0.16 mmol, 57% yield) was prepared following a procedure similar to that reported for 1 using [Cp\*RhCl<sub>2</sub>]<sub>2</sub> and NaQ<sup>S</sup> and was recrystallized from 1:1 CH<sub>2</sub>Cl<sub>2</sub>/light petroleum (40-60 °C). mp: 226-228 °C. Anal. Calcd for C<sub>34</sub>H<sub>34</sub>ClN<sub>2</sub>O<sub>2</sub>Rh: C, 63.71; H, 5.35; N, 4.37. Found: C, 63.90; H, 5.45; N, 4.20. IR (Nujol, cm<sup>-1</sup>): 1607s, 1591s, 1579s, 1531m, *v*(C<sup>...</sup>C, C<sup>...</sup>N), 459m, 278s *v*(Rh−Cl).<sup>1</sup>H NMR (CDCl<sub>3</sub>, 293 K): δ 1.43 (s, 15H, CH<sub>3Cp\*</sub>), 2.29 (s, 3H, 3-CH<sub>3</sub>), 5.72 (s, 1H, *CH*(C<sub>6</sub>H<sub>5</sub>)<sub>2</sub>), 7.10–7.41m, 7.93d (15H, N–C<sub>6</sub>H<sub>5</sub> and CH<sub>2</sub>(C<sub>6</sub>H<sub>5</sub>)<sub>2</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 293 K): δ 8.62 (s, CH<sub>3Cp\*</sub>), 17.57 (s, 3-CH<sub>3</sub>), 58.26 (s,  $CH(C_6H_5)_2$ ), 92.30 (d,  $C_{Cp^*}$ ,  $J(^{103}Rh-^{13}C) = 9.4$  Hz), 120.93, 124.98, 126.8, 127.17, 128.22, 128.56, 129.40, 129.60, 130.12, 138.87 (s,  $N-C_6H_5$  and  $CH_2(C_6H_5)_2$ ), 148.39 (s, C3), 161.80 (s, C5), 189.85 (s, CO), C4 not observed.

[Chloro(pentamethylcyclopentadienyl)(1-phenyl-3-methyl-4-(2,2-diphenylacetyl)pyrazolon-5-ato)iridium(III)], [Cp\*Ir-(Q<sup>S</sup>)Cl] (9). Orange compound 9 (0.120 g, 0.16 mmol, 55% yield) was prepared following a procedure similar to that reported for 3 using [IrCp\*Cl<sub>2</sub>]<sub>2</sub> and NaQ<sup>CH-Ph2</sup> and was recrystallized from 1:1 CH<sub>2</sub>Cl<sub>2</sub>/light petroleum (40-60 °C). mp: 151-154 °C. Anal. Calcd for C<sub>34</sub>H<sub>34</sub>ClIrN<sub>2</sub>O<sub>2</sub>: C, 55.92; H, 4.69; N, 3.84. Found: C, 55.88; H, 4.84; N, 3.83. IR (Nujol, cm<sup>-1</sup>): 1605s, 1591s, 1578s, 1532m, ν(C····C, C····N), 509w, 465w, 280s ν(Ir–Cl).<sup>1</sup>H NMR (CDCl<sub>3</sub>, 293 K): δ 1.39 (s, 15H, CH<sub>3Cp\*</sub>), 2.31 (s, 3H, 3-CH<sub>3</sub>), 5.73 (s, 1H, CH(C<sub>6</sub>H<sub>5</sub>)<sub>2</sub>), 7.10–7.55m, 7.95d (15H, N–C<sub>6</sub>H<sub>5</sub> and CH<sub>2</sub>(C<sub>6</sub>H<sub>5</sub>)<sub>2</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 293 K): δ 8.81 (s, CH<sub>3Cp\*</sub>), 17.42 (s, 3-CH<sub>3</sub>), 57.92 (s, CH(Ph)<sub>2</sub>), 83.60 (s, C<sub>Cp\*</sub>), 120.92, 125.21, 126.94, 127.26, 127.68, 128.26, 128.64, 129.07, 129.64, 130.12, 138.46, 141.23 (s,  $N-C_6H_5$  and  $CH_2(C_6H_5)_2$ , 148.08 (s, C3), 189.32 (s, CO), C4 not observed.

[(Pentamethylcyclopentadienyl)(1-phenyl-3-methyl-4acetylpyrazolon-5-ato)(acetonitrile)rhodium(III)]nitrate Trihydrate, [Cp\*Rh(Q<sup>Me</sup>)(MeCN)]NO<sub>3</sub>·3H<sub>2</sub>O (10). A CH<sub>3</sub>CN solution (10 mL) containing [Cp\*Rh(Q<sup>Me</sup>)Cl] (0.120 g, 0.24 mmol) and AgNO<sub>3</sub> (0.048 g, 0.28 mmol) under N<sub>2</sub> at room temperature was stirred overnight. After 48 h, a colorless precipitate formed, which was filtered of and shown to be AgCl. The clear yellow solution obtained was evaporated under vacuum; the yellow residue was washed with light petroleum (40–60 °C) and was identified as 10. mp: 200–201 °C. Anal. Calcd for C<sub>24</sub>H<sub>35</sub>N<sub>4</sub>O<sub>8</sub>Rh: C, 47.22; H, 5.78; N, 9.18. Found: C, 46.90; H, 5.81; N, 9.22. IR (Nujol, cm<sup>-1</sup>): 1604s, 1589s, 1574s, 1519s,  $\nu$ (C···C, C···N), 1450sh, 1277sbr  $\nu$ -(NO<sub>3</sub>), 514m, 456m.<sup>1</sup>H NMR (CDCl<sub>3</sub>, 293 K):  $\delta$  1.6 (s br, 21H, CH<sub>3Cp\*</sub> + H<sub>2</sub>O), 2.0 (s br, 3H, MeCN), 2.32 (s, 3H, 3-CH<sub>3</sub>), 2.41 (s, 3H, COCH<sub>3</sub>), 7.10–7.40, 7.92–7.96 (m, 5H, N-Ph). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 293 K):  $\delta$  8.83 (s, CH<sub>3Cp\*</sub>), 17.48 (s, 3-CH<sub>3</sub>), 27.83 (COCH<sub>3</sub>), 92.47, 92.61 (d, C<sub>Cp\*</sub>, J(<sup>103</sup>Rh<sup>-13</sup>C) = 10.5 Hz), 120.77 (s, C2 and C6<sub>Ph-Q</sub>), 125.19 (s, C4<sub>Ph-Q</sub>), 128.69 (s, C3 and C5<sub>Ph-Q</sub>), 138.92 (s, CI<sub>Ph-Q</sub>), 148.84 (s, C5<sub>Py</sub>).

[(Pentamethylcyclopentadienyl)(1-phenyl-3-methyl-4acetylpyrazolon-5-ato)(aqua)rhodium(III)]perchlorate, [Cp\*Rh- $(Q^{Me})(H_2O)$ ]ClO<sub>4</sub> (11). Compound 11 was prepared following a procedure similar to that reported for **10** using [Cp\*Rh(Q<sup>Me</sup>)Cl] and AgClO<sub>4</sub>. After 48 h, a pale-yellow precipitate formed, which was removed by filtration and shown to be AgCl and AgQ. The clear red-yellow solution obtained was evaporated under vacuum; the red-yellow residue was washed with light petroleum (40-60 °C) and was identified as a mixture of 11 and [Cp\*Rh(Cl)(H<sub>2</sub>O)<sub>2</sub>]-CIO<sub>4</sub>. Recrystallization from CH<sub>3</sub>CN/Et<sub>2</sub>O yields microcrystalline 11 (0.200 g, 0.35 mmol, 70% yield). mp: 230-233 °C. Anal. Calcd for C<sub>22</sub>H<sub>28</sub>ClN<sub>2</sub>O<sub>7</sub>Rh: C, 46.29; H, 4.94; N, 4.91. Found: C, 45.87; H, 5.10; N, 4.85. IR (Nujol, cm<sup>-1</sup>): 3400 br, 1606s, 1589sh, 1577s, 1530m, v(C<sup>...</sup>C, C<sup>...</sup>N), 1080sbr v(ClO<sub>4</sub>), 509w, 463m.<sup>1</sup>H NMR  $((CD_3)_2CO), 293K): \delta 1.73(s, 15H, CH_{3Cp^*}), 2.18 (s, 2H, H_2O),$ 2.37 (s, 3H, 3-CH<sub>3</sub>), 2.56 (s, 3H, COCH<sub>3</sub>), 7.20-7.37m, 7.42-7.58m, 7.98d (5H, N-Ph). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 293 K): δ 8.39 (s, CH<sub>3Cp\*</sub>), 16.92 (s, 3-CH<sub>3</sub>), 27.67 (COCH<sub>3</sub>), 94.43, 94.57(d, C<sub>Cp\*</sub>,  $J(^{103}\text{Rh}-^{13}\text{C}) = 10.5 \text{ Hz}$ , 105.47 (s, C4), 120.98, 125.93, 129.08, 138.79 (s, N-C<sub>6</sub>H<sub>5</sub> of Q), 149.59 (s, C5<sub>Py</sub>), 162.35 (s, C5), 192.34 (s, CO).

[Bromo(pentamethylcyclopentadienyl)(1-phenyl-3-methyl-4-(2-phenylacetyl)pyrazolon-5-ato)rhodium(III)], [RhCp\*(Q<sup>Bn</sup>)-Br] (12). [Cp\*RhCl<sub>2</sub>]<sub>2</sub> (0.140 g, 0.22 mmol) was dissolved in 10 mL of THF, and 0.45 mL of Grignard reagent (MgCH<sub>3</sub>Br solution, 1.0 M in hexane) was added. The red solution was stirred for 48 h under N<sub>2</sub> at room temperature, evaporated under vacuum, and treated with CH<sub>2</sub>Cl<sub>2</sub>. A colorless precipitate formed, which was filtered off and shown to be MgCl<sub>2</sub>. The filtrate was dried under vacuum; then 10 mL of toluene was added to give a red solution, and finally NaQ<sup>Bn</sup> was added. The mixture was stirred overnight under N2 at room temperature to give a red-orange precipitate, which was filtered off, washed with 5 mL of toluene, and then recrystallized from 1:1 CH<sub>2</sub>Cl<sub>2</sub>/light petroleum (40-60 °C); it has been identified as 12. Anal. Calcd for C<sub>28</sub>H<sub>30</sub>BrN<sub>2</sub>O<sub>2</sub>Rh: C, 55.19; H, 4.96; N, 4.60. Found: C, 54.98; H, 5.10; N, 4.30. IR (Nujol, cm<sup>-1</sup>): 1609s, 1591s, 1581s, 1528m v(C--C, C--N), 512w, 450w. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 293 K): δ 1.52 (s, 15H, CH<sub>3Cp\*</sub>), 2.42 (s, 3H, 3-CH<sub>3</sub>), 3.79, 3.87, 4.21, 4.29 (q,  $2H_{gem}$ , COCH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>, <sup>2</sup>J(A-X) = 15.40 Hz,  $\Delta \delta v/J$  = 5.57), 7.12–7.40m, 7.94d (10H, N–C<sub>6</sub>H<sub>5</sub>

[(Pentamethylcyclopentadienyl)(1-phenyl-3-methyl-4acetylpyrazolon-5-ato)(triphenylphosphine)rhodium(III)]chloride, [Cp\*Rh(Q<sup>Me</sup>)(PPh<sub>3</sub>)]Cl (13). A dichloromethane solution (10 mL) containing RhCp\*(Q<sup>Me</sup>)Cl (0.085 g, 0.17 mmol) and PPh<sub>3</sub> (0.044 g, 0.17 mmol) was stirred for 72 h under N<sub>2</sub> at room temperature. The orange solution was dried in a vacuum and recrystallized from 1:1 CH<sub>2</sub>Cl<sub>2</sub>/light petroleum (40–60 °C), and the crystals were shown to be compound **13** (0.102 g, 0.136 mmol, 80% yield). mp: 100 °C (dec). Anal. Calcd for C<sub>40</sub>H<sub>41</sub>ClN<sub>2</sub>O<sub>2</sub>PRh, C, 63.96; H, 5.50; N, 3.73. Found: C, 64.12; H, 5.68; N, 3.57. IR (Nujol, cm<sup>-1</sup>): 3180w  $\nu$ (Ph), 1610sh, 1592m, 1570s,  $\nu$ (C···C, C···N), 1096s, 1021s, 521s, 511s, 499msh, 396vs. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 293 K):  $\delta$  1.15 (d, 15H, CH<sub>3Cp\*</sub>, <sup>4</sup>J(<sup>31</sup>P-<sup>1</sup>H) = 3.36 Hz), 1.34 (d,

and  $COCH_2C_6H_5$ ).

15H,  $CH_{3Cp^*}$ ,  ${}^{4}J({}^{31}P^{-1}H) = 3.66$  Hz), 2.08 (d, 3H, 3- $CH_3$ ), 2.38 (d, 3H, COCH<sub>3</sub>), 7.15–7.82m, 8.08m (5H, N– $C_6H_5$ , 15H, P( $C_6H_5$ )<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 293 K):  $\delta$  8.96 (d,  ${}^{2}J({}^{103}Rh^{-13}C) = 4.55$  Hz,  $CH_{3Cp^*}$ ), 9.01 (d,  ${}^{2}J({}^{103}Rh^{-13}C) = 4.46$  Hz,  $CH_{3Cp^*}$ ), 16.90, 17.22 (s, 3- $CH_3$ ), 27.72, 28.24 (COCH<sub>3</sub>), 99.34 (d,  ${}^{1}J({}^{103}Rh^{-13}C) = 6.7$  Hz,  $C_{Cp^*}$ ), 99.38 (d,  ${}^{1}J({}^{103}Rh^{-13}C) = 6.8$  Hz,  $C_{Cp^*}$ ), 106.12, 104.30 (s, *C4*), 118.93, 120.45, 126.10, 127.14, 129.55, 129.71, 138.17, 138.82 (s, N– $C_6H_5$  of Q), 128.86 (d,  ${}^{3}J({}^{31}P^{-13}C) = 11.06$  Hz, *m*-C), 129.42 (d,  ${}^{3}J({}^{31}P^{-13}C) = 10.90$  Hz, *m*-C), 129.75 (d,  ${}^{4}J({}^{31}P^{-13}C) = 3.82$  Hz, *p*-C), 131.32 (sbr, *p*-C), 132.71 (d,  ${}^{1}J({}^{31}P^{-13}C) = 15.64$  Hz, *i*-C), 132.77 (d,  ${}^{1}J({}^{31}P^{-13}C) = 16.78$  Hz, *i*-C), 134.74, (d,  ${}^{2}J({}^{31}P^{-13}C) = 10.30$  Hz, *o*-C), 135.68 (d,  ${}^{2}J({}^{31}P^{-13}C) = 9.54$  Hz, *o*-C), 148.69, 149.82 (s, *C3*), 161.95, 163.84 (s, *C5*), 191.71, 193.02 (s, *CO*).<sup>31</sup>P NMR (CDCl<sub>3</sub>, 293 K): 30.71, (d,  ${}^{1}J({}^{31}P^{-Rh}) = 147.7$  Hz), 30.44 (d,  ${}^{1}J({}^{31}P^{-Rh}) = 143.9$  Hz).

[(Pentamethylcyclopentadienyl)(1-phenyl-3-methyl-4-(3,3dimethylbutanoyl)pyrazolon-5-ato)(triphenylphosphine)rhodium(III)]chloride, [Cp\*Rh(QPiv)(PPh3)]Cl (14). Red compound 14 (0.167 g, 0.20 mmol, 76% yield) was prepared following a procedure similar to that reported for **13** using [Cp\*Rh(Q<sup>Piv</sup>)Cl] and PPh<sub>3</sub>. mp: 100 °C (dec). Anal. Calcd for C<sub>44</sub>H<sub>49</sub>ClN<sub>2</sub>O<sub>2</sub>PRh: C, 65.47; H, 6.12; N, 3.47. Found: C, 65.51; H, 6.28; N, 3.42. IR (Nujol, cm<sup>-1</sup>): 1621m, 1589m, 1566s, 1522w v(C. C. C. N), 523s, 510m, 497m, 394sbr. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 293 K): δ 0.90 (s, 9H, CH<sub>2</sub>C(CH<sub>3</sub>)<sub>3</sub>), 1.06 (s, 9H, CH<sub>2</sub>C(CH<sub>3</sub>)<sub>3</sub>), 1.10 (d, 15H, CH<sub>3Cp\*</sub>,  ${}^{4}J({}^{31}P-{}^{1}H) = 2.60 \text{ Hz}$ , 1.36 (d, 15H, CH<sub>3Cp\*</sub>,  ${}^{4}J({}^{31}P-{}^{1}H) = 2.66$ Hz), 2.23 (s, 3H, 3-CH<sub>3</sub>), 2.36 (m, 3H, 3-CH<sub>3</sub>), 7.30-7.50, 7.70-7.85, 8.05 (m, 5H, N-Ph). 2.08 (d, 3H, 3-CH<sub>3</sub>), 2.38 (d, 3H, COCH<sub>3</sub>), 7.15-7.82m, 8.08m (5H, N-C<sub>6</sub>H<sub>5</sub>, 15H, P(C<sub>6</sub>H<sub>5</sub>)<sub>3</sub>).<sup>13</sup>C NMR (CDCl<sub>3</sub>, 293 K):  $\delta$  9.02 (d, <sup>2</sup>J(<sup>103</sup>Rh-<sup>13</sup>C) = 2.87 Hz,  $CH_{3Cp^*}$ ), 9.12 (d,  ${}^{2}J({}^{103}Rh-{}^{13}C) = 2.65$  Hz,  $CH_{3Cp^*}$ ), 17.92, 18.40 (s, 3-CH<sub>3</sub>), 29.85, 30.41 (s, CH<sub>2</sub>C(CH<sub>3</sub>)<sub>3</sub>), 49.87, 50.12 (s, CH<sub>2</sub>C- $(CH_3)_3$ ), 99.70 (d,  ${}^{1}J({}^{103}Rh{-}^{13}C) = 6.1$  Hz,  $C_{Cp^*}$ ), 99.95 (d,  ${}^{1}J({}^{103}\text{Rh}{-}{}^{13}\text{C}) = 5.7 \text{ Hz}, \text{ C}_{\text{Cp}*}), 120.45, 121.10, 126.02, 126.74,$ 127.92, 128.62, 137.50, 138.17 (s, N-C<sub>6</sub> $H_5$ ), 127.82 (d,  ${}^{3}J({}^{31}P ^{13}$ C) = 14.55 Hz, *m*-C), 128.91 (d,  $^{3}J(^{31}P-^{13}C) = 18.22$  Hz, *m*-C),  $128.30 (d, {}^{4}J({}^{31}P-{}^{13}C) = 4.27 Hz, p-C), 130.76 (sbr, p-C), 133.10$  $(d, {}^{1}J({}^{31}P-{}^{13}C) = 19.42 \text{ Hz}, i-C), 133.27 (d, {}^{1}J({}^{31}P-{}^{13}C) = 23.10$ Hz, *i*-C), 134.47, (d,  ${}^{2}J({}^{31}P-{}^{13}C) = 10.35$  Hz, *o*-C), 134.93 (d,  ${}^{2}J({}^{31}P-{}^{13}C) = 9.67 \text{ Hz}, o-C), 147.14, 148.42 (s, C3), 160.67, 162.18$ (s, C5), 190.80, 192.62 (s, CO). <sup>31</sup>P NMR (CDCl<sub>3</sub>, 293 K): δ 30.04 (d,  ${}^{1}J({}^{31}P-Rh) = 149.8$  Hz), 30.43 (d,  ${}^{1}J({}^{31}P-Rh) = 144.1$  Hz).

[(Pentamethylcyclopentadienyl)(1-phenyl-3-methyl-4-(2,2diphenylacetyl)pyrazolon-5-ato)(triphenylphosphine)rhodium(III)]chloride, [RhCp\*(Q<sup>S</sup>)(PPh<sub>3</sub>)]Cl (15). Orange compound 15 (0.150 g, 0.16 mmol, 75% yield) was prepared following a procedure similar to that reported for 13 using RhCp\*(Q<sup>S</sup>)Cl and PPh<sub>3</sub>. Anal. Calcd for C<sub>52</sub>H<sub>49</sub>ClN<sub>2</sub>O<sub>2</sub>PRh: C, 69.14; H, 5.47; N, 3.10. Found: C, 68.80; H, 5.28; N, 3.02. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 293 K):  $\delta$  0.84 (d, 15H, CH<sub>3Cp\*</sub>, <sup>4</sup>J(<sup>31</sup>P-<sup>1</sup>H) = 3.20 Hz), 1.37 (d, 15H, CH<sub>3Cp\*</sub>, <sup>4</sup>J(<sup>31</sup>P-<sup>1</sup>H) = 3.78 Hz), 2.01 (s, 3H, 3-CH<sub>3</sub>), 2.34 (s, 3H, 3-CH<sub>3</sub>), 5.22 (s, 1H, CH(C<sub>6</sub>H<sub>5</sub>)<sub>2</sub>), 5.35 (s, 1H, CH(C<sub>6</sub>H<sub>5</sub>)<sub>2</sub>), 7.00-8.01 (m, 5H, N-C<sub>6</sub>H<sub>5</sub>, 15H, P(C<sub>6</sub>H<sub>5</sub>)<sub>3</sub>). <sup>31</sup>P NMR (CDCl<sub>3</sub>, 293 K):  $\delta$  28.97 (d, <sup>1</sup>J(<sup>31</sup>P-Rh) = 149.6 Hz), 30.44 (d, <sup>1</sup>J(<sup>31</sup>P-Rh) = 144.1 Hz). Compound **15** has been also obtained when the reaction was carried out at -80 °C for 5 min.

**X-ray Diffraction Studies.** Full spheres of CCD area-detector diffractometer data were measured at ca. 153 K (Bruker AXS instrument,  $\omega$ -scans; monochromatic Mo K $\alpha$  radiation,  $\lambda = 0.71073$  Å) yielding  $N_{\text{t(otal)}}$  reflections; those merging to N unique ( $R_{\text{int}}$  quoted) after "empirical"/multiscan absorption correction (proprietary software),  $N_{\text{o}}$  with  $F > 4\sigma(F)$  considered "observed", were used in the full-matrix least-squares refinement, refining anisotropic

#### Rhodium(III) Cyclopentadienyl β-diketonate Complexes

Table 1.	Crystal	and	Refinement Data	
----------	---------	-----	-----------------	--

	$1^{a}$	2	$4^{b}$	6
formula	C22H26ClN2O2Rh	C22H26ClIrN2O2	$C_{26}H_{34}N_2O_2Rh$	C <sub>28</sub> H <sub>30</sub> ClN <sub>2</sub> O <sub>2</sub> Rh
$M_{ m r}$	488.8	578.1	544.9	564.9
cryst syst	monoclinic	monoclinic	monoclinic	monoclinic
space group	$P2_1/n$ (No. 14)	$P2_1/n$ (No. 14)	$P2_1/n$ (No. 14)	$P2_1/c$ (No. 14)
a (Å)	8.540(1)	8.6997(6)	16.059(5)	7.582(2)
b (Å)	17.163(3)	17.049(1)	19.606(7)	21.345(6)
c (Å)	13.769(2)	13.9360(9)	8.081(3)	15.458(5)
α (deg)				
$\beta$ (deg)	97.287(4)	96.470(2)	92.177(7)	102.037(7)
$\gamma$ (deg)				
$V(Å^3)$	2002	2054	2542	2447
$D_{\rm c} ({\rm g}{\rm cm}^{-3})$	1.622	1.869	1.424	1.533
Z	4	4	4	4
$\mu (\text{mm}^{-1})$	1.01	6.7	0.80	0.84
specimen (mm)	$0.44 \times 0.22 \times 0.15$	$0.12 \times 0.08 \times 0.06$	$0.19 \times 0.14 \times 0.02$	$0.19 \times 0.14 \times 0.08$
$\hat{T}'_{\min/\max}$	0.84	0.73	0.58	0.90
$2\theta_{\rm max}$ (deg)	75	75	50	55
Nt	42157	42837	20656	25402
$N(R_{\rm int})$	10628 (0.039)	10806 (0.045)	4564 (0.16)	5542 (0.062)
No	8115	7799	1685	4294
R	0.044	0.035	0.079	0.043
$R_{ m w}$	0.050	0.040	0.103	0.067
	7		8	12
formula	7 C <sub>28</sub> H <sub>30</sub> ClIrN <sub>2</sub> O <sub>2</sub>		8 C <sub>34</sub> H <sub>34</sub> ClN <sub>2</sub> O <sub>2</sub> Rh	12 C <sub>28</sub> H <sub>30</sub> BrN <sub>2</sub> O <sub>2</sub> Rh
formula M <sub>r</sub>	7 C <sub>28</sub> H <sub>30</sub> ClIrN <sub>2</sub> O <sub>2</sub> 654.2		<b>8</b> C <sub>34</sub> H <sub>34</sub> ClN <sub>2</sub> O <sub>2</sub> Rh 641.0	12 C <sub>28</sub> H <sub>30</sub> BrN <sub>2</sub> O <sub>2</sub> Rh 609.4
formula <i>M</i> r cryst syst	7 C <sub>28</sub> H <sub>30</sub> ClIrN <sub>2</sub> O <sub>2</sub> 654.2 Monoclinic		8 C <sub>34</sub> H <sub>34</sub> ClN <sub>2</sub> O <sub>2</sub> Rh 641.0 Monoclinic	12 C <sub>28</sub> H <sub>30</sub> BrN <sub>2</sub> O <sub>2</sub> Rh 609.4 Monoclinic
formula <i>M</i> <sub>r</sub> cryst syst space group	7 C <sub>28</sub> H <sub>30</sub> ClIrN <sub>2</sub> O <sub>2</sub> 654.2 Monoclinic P2 <sub>1</sub> /c (#14)		8 C <sub>34</sub> H <sub>34</sub> ClN <sub>2</sub> O <sub>2</sub> Rh 641.0 Monoclinic PĪ(#2)	$     12     C_{28}H_{30}BrN_2O_2Rh     609.4     Monoclinic     P2_1/c (#14) $
formula $M_r$ cryst syst space group a (Å)	7 C <sub>28</sub> H <sub>30</sub> ClIrN <sub>2</sub> O <sub>2</sub> 654.2 Monoclinic P2 <sub>1</sub> /c (#14) 7.5905(7)		8 C <sub>34</sub> H <sub>34</sub> ClN <sub>2</sub> O <sub>2</sub> Rh 641.0 Monoclinic PĪ(#2) 8.2875(6)	$\begin{array}{c} 12 \\ \hline C_{28}H_{30}BrN_2O_2Rh \\ 609.4 \\ Monoclinic \\ P2_{1/c} (\#14) \\ 7.618(1) \end{array}$
formula $M_r$ cryst syst space group a (Å) b (Å)	$\begin{array}{c} & 7 \\ \hline C_{28}H_{30}\text{ClIrN}_{2}\text{O}_{2} \\ 654.2 \\ \text{Monoclinic} \\ P2_{1/c} \ (\#14) \\ 7.5905(7) \\ 21.337(2) \end{array}$		8 C <sub>34</sub> H <sub>34</sub> ClN <sub>2</sub> O <sub>2</sub> Rh 641.0 Monoclinic PĪ(#2) 8.2875(6) 13.778(1)	$\begin{array}{c} 12 \\ \hline C_{28}H_{30}BrN_2O_2Rh \\ 609.4 \\ Monoclinic \\ P2_{1/c} (\#14) \\ 7.618(1) \\ 21.329(4) \end{array}$
formula $M_r$ cryst syst space group a (Å) b (Å) c (Å)	$\begin{array}{c} & 7 \\ \hline C_{28}H_{30}\text{ClIrN}_{2}\text{O}_{2} \\ 654.2 \\ \text{Monoclinic} \\ P2_{1/c} \ (\#14) \\ 7.5905(7) \\ 21.337(2) \\ 15.560(2) \end{array}$		8 C <sub>34</sub> H <sub>34</sub> ClN <sub>2</sub> O <sub>2</sub> Rh 641.0 Monoclinic PĪ(#2) 8.2875(6) 13.778(1) 14.610(1)	$\begin{array}{c} 12 \\ \hline C_{28}H_{30}BrN_2O_2Rh \\ 609.4 \\ Monoclinic \\ P2_{1/c} (\#14) \\ 7.618(1) \\ 21.329(4) \\ 15.605(3) \end{array}$
formula $M_r$ cryst syst space group a (Å) b (Å) c (Å) $\alpha$ (deg)	$\begin{array}{c} 7 \\ C_{28}H_{30}CIIrN_{2}O_{2} \\ 654.2 \\ Monoclinic \\ P2_{1/c} (\#14) \\ 7.5905(7) \\ 21.337(2) \\ 15.560(2) \end{array}$		<b>8</b> C <sub>34</sub> H <sub>34</sub> ClN <sub>2</sub> O <sub>2</sub> Rh 641.0 Monoclinic PĪ(#2) 8.2875(6) 13.778(1) 14.610(1) 109.429(2)	$\begin{array}{c} 12 \\ \hline C_{28}H_{30}BrN_2O_2Rh \\ 609.4 \\ Monoclinic \\ P2_{1/c} (\#14) \\ 7.618(1) \\ 21.329(4) \\ 15.605(3) \end{array}$
formula $M_r$ cryst syst space group a (Å) b (Å) c (Å) $\alpha$ (deg) $\beta$ (deg)	$\begin{array}{c} & 7 \\ C_{28}H_{30}\text{CIIrN}_2\text{O}_2 \\ 654.2 \\ \text{Monoclinic} \\ P2_{1/c} \ (\#14) \\ 7.5905(7) \\ 21.337(2) \\ 15.560(2) \\ 101.893(2) \end{array}$		8 C <sub>34</sub> H <sub>34</sub> ClN <sub>2</sub> O <sub>2</sub> Rh 641.0 Monoclinic PĪ(#2) 8.2875(6) 13.778(1) 14.610(1) 109.429(2) 95.937(2)	$\begin{array}{c} 12 \\ \hline C_{28}H_{30}BrN_2O_2Rh \\ 609.4 \\ Monoclinic \\ P2_{1/c} (\#14) \\ 7.618(1) \\ 21.329(4) \\ 15.605(3) \\ 101.784(3) \end{array}$
formula $M_r$ cryst syst space group a (Å) b (Å) c (Å) $\alpha$ (deg) $\beta$ (deg) $\gamma$ (deg)	$\begin{array}{c} & 7 \\ C_{28}H_{30}\text{CIIrN}_2\text{O}_2 \\ 654.2 \\ \text{Monoclinic} \\ P2_{1/c} \ (\#14) \\ 7.5905(7) \\ 21.337(2) \\ 15.560(2) \\ 101.893(2) \end{array}$		<b>8</b> C <sub>34</sub> H <sub>34</sub> ClN <sub>2</sub> O <sub>2</sub> Rh 641.0 Monoclinic PĪ(#2) 8.2875(6) 13.778(1) 14.610(1) 109.429(2) 95.937(2) 106.875(2)	$\begin{array}{c} 12\\ \hline C_{28}H_{30}BrN_{2}O_{2}Rh\\ 609.4\\ \hline Monoclinic\\ P2_{1/c} (\#14)\\ 7.618(1)\\ 21.329(4)\\ 15.605(3)\\ 101.784(3) \end{array}$
formula $M_r$ cryst syst space group a (Å) b (Å) c (Å) $\alpha$ (deg) $\beta$ (deg) $\gamma$ (deg) V (Å <sup>3</sup> )	$\begin{array}{c} & 7 \\ C_{28}H_{30}\text{CIIrN}_2\text{O}_2 \\ 654.2 \\ \text{Monoclinic} \\ P2_1/c \ (\#14) \\ 7.5905(7) \\ 21.337(2) \\ 15.560(2) \\ 101.893(2) \\ 2466 \end{array}$		$\frac{8}{C_{34}H_{34}ClN_2O_2Rh} \\ 641.0 \\ Monoclinic \\ P\bar{1}(#2) \\ 8.2875(6) \\ 13.778(1) \\ 14.610(1) \\ 109.429(2) \\ 95.937(2) \\ 106.875(2) \\ 1468 \\ \\ \end{bmatrix}$	$\begin{array}{c} 12\\ \hline C_{28}H_{30}BrN_{2}O_{2}Rh\\ 609.4\\ \hline Monoclinic\\ P2_{1/c} (\#14)\\ 7.618(1)\\ 21.329(4)\\ 15.605(3)\\ 101.784(3)\\ 2482 \end{array}$
formula $M_r$ cryst syst space group a (Å) b (Å) c (Å) $\alpha$ (deg) $\beta$ (deg) $\gamma$ (deg) V (Å <sup>3</sup> ) $D_c$ (g cm <sup>-3</sup> )	$\begin{array}{c} & 7 \\ C_{28}H_{30}\text{CIIrN}_2\text{O}_2 \\ 654.2 \\ \text{Monoclinic} \\ P2_{1/c} \ (\#14) \\ 7.5905(7) \\ 21.337(2) \\ 15.560(2) \\ 101.893(2) \\ 2466 \\ 1.762 \end{array}$		$\frac{8}{C_{34}H_{34}ClN_2O_2Rh} \\ 641.0 \\ Monoclinic \\ P\bar{1}(#2) \\ 8.2875(6) \\ 13.778(1) \\ 14.610(1) \\ 109.429(2) \\ 95.937(2) \\ 106.875(2) \\ 1468 \\ 1.450 \\ \end{bmatrix}$	$\begin{array}{c} 12 \\ \hline C_{28}H_{30}BrN_{2}O_{2}Rh \\ 609.4 \\ \hline Monoclinic \\ P2_{1/c} (\#14) \\ 7.618(1) \\ 21.329(4) \\ 15.605(3) \\ 101.784(3) \\ 2482 \\ 1.630 \\ \end{array}$
formula $M_r$ cryst syst space group $a (\mathring{A})$ $b (\mathring{A})$ $c (\mathring{A})$ $\alpha (deg)$ $\beta (deg)$ $\gamma (deg)$ $\gamma (deg)$ $V (\mathring{A}^3)$ $D_c (g cm^{-3})$ Z	$\begin{array}{c} & 7 \\ C_{28}H_{30}\text{CIIrN}_2\text{O}_2 \\ 654.2 \\ \text{Monoclinic} \\ P2_{1/c} (\#14) \\ 7.5905(7) \\ 21.337(2) \\ 15.560(2) \\ 101.893(2) \\ 2466 \\ 1.762 \\ 4 \end{array}$		<b>8</b> C <sub>34</sub> H <sub>34</sub> ClN <sub>2</sub> O <sub>2</sub> Rh 641.0 Monoclinic PĪ(#2) 8.2875(6) 13.778(1) 14.610(1) 109.429(2) 95.937(2) 106.875(2) 1468 1.450 2	$\begin{array}{c} 12 \\ \hline C_{28}H_{30}BrN_{2}O_{2}Rh \\ 609.4 \\ Monoclinic \\ P2_{1/c} (\#14) \\ 7.618(1) \\ 21.329(4) \\ 15.605(3) \\ 101.784(3) \\ 2482 \\ 1.630 \\ 4 \end{array}$
formula $M_r$ cryst syst space group $a (\mathring{A})$ $b (\mathring{A})$ $c (\mathring{A})$ $\alpha (deg)$ $\beta (deg)$ $\gamma (deg)$ $V (\mathring{A}^3)$ $D_c (g \text{ cm}^{-3})$ Z $\mu (\text{mm}^{-1})$	$\begin{array}{c} & 7 \\ C_{28}H_{30}\text{CIIrN}_2\text{O}_2 \\ 654.2 \\ \text{Monoclinic} \\ P2_{1/c} \ (\#14) \\ 7.5905(7) \\ 21.337(2) \\ 15.560(2) \\ 101.893(2) \\ 2466 \\ 1.762 \\ 4 \\ 5.6 \end{array}$		<b>8</b> C <sub>34</sub> H <sub>34</sub> ClN <sub>2</sub> O <sub>2</sub> Rh 641.0 Monoclinic PĪ(#2) 8.2875(6) 13.778(1) 14.610(1) 109.429(2) 95.937(2) 106.875(2) 1468 1.450 2 0.71	$\begin{array}{c} 12 \\ \hline C_{28}H_{30}BrN_{2}O_{2}Rh \\ 609.4 \\ \hline Monoclinic \\ P2_{1/c} (\#14) \\ 7.618(1) \\ 21.329(4) \\ 15.605(3) \\ 101.784(3) \\ 2482 \\ 1.630 \\ 4 \\ 2.3 \end{array}$
formula $M_r$ cryst syst space group $a (\mathring{A})$ $b (\mathring{A})$ $c (\mathring{A})$ $\alpha (deg)$ $\beta (deg)$ $\gamma (deg)$ $V (\mathring{A}^3)$ $D_c (g cm^{-3})$ Z $\mu (mm^{-1})$ specimen (mm)	$\begin{array}{c} & 7 \\ & C_{28}H_{30}CIIrN_{2}O_{2} \\ & 654.2 \\ & Monoclinic \\ P2_{1/c} (\#14) \\ & 7.5905(7) \\ & 21.337(2) \\ & 15.560(2) \\ & 101.893(2) \\ & 2466 \\ & 1.762 \\ & 4 \\ & 5.6 \\ & 0.18 \times 0.10 \times 0.08 \end{array}$		$\frac{8}{C_{34}H_{34}ClN_2O_2Rh}{641.0}\\ \frac{Monoclinic}{PI(#2)}\\ 8.2875(6)\\ 13.778(1)\\ 14.610(1)\\ 109.429(2)\\ 95.937(2)\\ 106.875(2)\\ 1468\\ 1.450\\ 2\\ 0.71\\ 0.15\times 0.09\times 0.06\\ \end{array}$	$\begin{array}{c} 12 \\ \hline C_{28}H_{30}BrN_2O_2Rh \\ 609.4 \\ Monoclinic \\ P2_{1/c} (\#14) \\ 7.618(1) \\ 21.329(4) \\ 15.605(3) \\ 101.784(3) \\ 2482 \\ 1.630 \\ 4 \\ 2.3 \\ 0.15 \times 0.09 \times 0.07 \end{array}$
formula $M_r$ cryst syst space group a (Å) b (Å) c (Å) $\alpha$ (deg) $\beta$ (deg) $\gamma$ (deg) $\gamma$ (deg) V (Å <sup>3</sup> ) $D_c$ (g cm <sup>-3</sup> ) Z $\mu$ (mm <sup>-1</sup> ) specimen (mm) $T'_{min/max}$	$\begin{array}{c} & 7 \\ C_{28}H_{30}CIIrN_{2}O_{2} \\ 654.2 \\ Monoclinic \\ P2_{1/c} (\#14) \\ 7.5905(7) \\ 21.337(2) \\ 15.560(2) \\ 101.893(2) \\ 2466 \\ 1.762 \\ 4 \\ 5.6 \\ 0.18 \times 0.10 \times 0.08 \\ 0.65 \end{array}$		$\frac{8}{C_{34}H_{34}ClN_2O_2Rh}{641.0}\\ \frac{641.0}{Monoclinic}\\ P\overline{l}(\#2)\\ 8.2875(6)\\ 13.778(1)\\ 14.610(1)\\ 109.429(2)\\ 95.937(2)\\ 106.875(2)\\ 1468\\ 1.450\\ 2\\ 0.71\\ 0.15\times 0.09\times 0.06\\ 0.92 \\ \end{bmatrix}$	$\begin{array}{c} 12\\ \hline C_{28}H_{30}BrN_2O_2Rh\\ 609.4\\ \hline Monoclinic\\ P2_{1/c}~(\#14)\\ 7.618(1)\\ 21.329(4)\\ 15.605(3)\\ 101.784(3)\\ 2482\\ 1.630\\ 4\\ 2.3\\ 0.15\times 0.09\times 0.07\\ 0.84\\ \end{array}$
formula $M_r$ cryst syst space group a (Å) b (Å) c (Å) $\alpha$ (deg) $\beta$ (deg) $\gamma$ (deg) $\gamma$ (deg) V (Å <sup>3</sup> ) $D_c$ (g cm <sup>-3</sup> ) Z $\mu$ (mm <sup>-1</sup> ) specimen (mm) 'T' <sub>min/max</sub> $2\theta_{max}$ (deg)	$\begin{array}{c} & 7 \\ C_{28}H_{30}CIIrN_{2}O_{2} \\ 654.2 \\ Monoclinic \\ P2_{1/c} (\#14) \\ 7.5905(7) \\ 21.337(2) \\ 15.560(2) \\ 101.893(2) \\ 2466 \\ 1.762 \\ 4 \\ 5.6 \\ 0.18 \times 0.10 \times 0.08 \\ 0.65 \\ 75 \end{array}$		$\begin{array}{r} 8 \\ \hline C_{34}H_{34}ClN_2O_2Rh \\ 641.0 \\ Monoclinic \\ P\bar{1}(\#2) \\ 8.2875(6) \\ 13.778(1) \\ 14.610(1) \\ 109.429(2) \\ 95.937(2) \\ 106.875(2) \\ 1468 \\ 1.450 \\ 2 \\ 0.71 \\ 0.15 \times 0.09 \times 0.06 \\ 0.92 \\ 75 \end{array}$	$\begin{array}{c} 12\\ \hline C_{28}H_{30}BrN_2O_2Rh\\ 609.4\\ \hline Monoclinic\\ P2_{1/c}~(\#14)\\ 7.618(1)\\ 21.329(4)\\ 15.605(3)\\ \hline 101.784(3)\\ 2482\\ 1.630\\ 4\\ 2.3\\ 0.15\times 0.09\times 0.07\\ 0.84\\ 50\\ \end{array}$
formula $M_r$ cryst syst space group a (Å) b (Å) c (Å) $\alpha$ (deg) $\beta$ (deg) $\gamma$ (deg) V (Å <sup>3</sup> ) $D_c$ (g cm <sup>-3</sup> ) Z $\mu$ (mm <sup>-1</sup> ) specimen (mm) $T'_{min/max}$ $2\theta_{max}$ (deg) $N_t$	$\begin{array}{c} & 7 \\ C_{28}H_{30}\text{CIIrN}_2\text{O}_2 \\ 654.2 \\ \text{Monoclinic} \\ P2_{1/c} (\#14) \\ 7.5905(7) \\ 21.337(2) \\ 15.560(2) \\ 101.893(2) \\ 2466 \\ 1.762 \\ 4 \\ 5.6 \\ 0.18 \times 0.10 \times 0.08 \\ 0.65 \\ 75 \\ 51205 \end{array}$		$\begin{array}{r} 8 \\ \hline C_{34}H_{34}ClN_2O_2Rh \\ 641.0 \\ Monoclinic \\ P\bar{1}(\#2) \\ 8.2875(6) \\ 13.778(1) \\ 14.610(1) \\ 109.429(2) \\ 95.937(2) \\ 106.875(2) \\ 1468 \\ 1.450 \\ 2 \\ 0.71 \\ 0.15 \times 0.09 \times 0.06 \\ 0.92 \\ 75 \\ 27373 \end{array}$	$\begin{array}{c} 12\\ \hline C_{28}H_{30}BrN_2O_2Rh\\ 609.4\\ Monoclinic\\ P2_{1/c} (\#14)\\ 7.618(1)\\ 21.329(4)\\ 15.605(3)\\ 101.784(3)\\ 2482\\ 1.630\\ 4\\ 2.3\\ 0.15\times 0.09\times 0.07\\ 0.84\\ 50\\ 17150\\ \end{array}$
formula $M_r$ cryst syst space group a (Å) b (Å) c (Å) $\alpha$ (deg) $\beta$ (deg) $\gamma$ (deg) V (Å <sup>3</sup> ) $D_c$ (g cm <sup>-3</sup> ) Z $\mu$ (mm <sup>-1</sup> ) specimen (mm) $T'_{min/max}$ $2\theta_{max}$ (deg) $N_t$ $N$ ( $R_{int}$ )	$\begin{array}{c} & 7 \\ C_{28}H_{30}{\rm CIIrN_2O_2} \\ 654.2 \\ {\rm Monoclinic} \\ P_{21/c} (\#14) \\ 7.5905(7) \\ 21.337(2) \\ 15.560(2) \\ 101.893(2) \\ 2466 \\ 1.762 \\ 4 \\ 5.6 \\ 0.18 \times 0.10 \times 0.08 \\ 0.65 \\ 75 \\ 51205 \\ 12742 (0.048) \\ \end{array}$		$\frac{8}{C_{34}H_{34}ClN_2O_2Rh} \\ 641.0 \\ Monoclinic \\ P\bar{1}(\#2) \\ 8.2875(6) \\ 13.778(1) \\ 14.610(1) \\ 109.429(2) \\ 95.937(2) \\ 106.875(2) \\ 1468 \\ 1.450 \\ 2 \\ 0.71 \\ 0.15 \times 0.09 \times 0.06 \\ 0.92 \\ 75 \\ 27373 \\ 15079 (0.025) \\ \end{cases}$	$\begin{array}{c} 12\\ \hline C_{28}H_{30}BrN_{2}O_{2}Rh\\ 609.4\\ \hline Monoclinic\\ P2_{1/c} (\#14)\\ 7.618(1)\\ 21.329(4)\\ 15.605(3)\\ 101.784(3)\\ 2482\\ 1.630\\ 4\\ 2.3\\ 0.15\times 0.09\times 0.07\\ 0.84\\ 50\\ 17150\\ 4512 (0.054)\\ \end{array}$
formula $M_r$ cryst syst space group a (Å) b (Å) c (Å) $\alpha$ (deg) $\beta$ (deg) $\gamma$ (deg) V (Å <sup>3</sup> ) $D_c$ (g cm <sup>-3</sup> ) Z $\mu$ (mm <sup>-1</sup> ) specimen (mm) $'T'_{min/max}$ $2\theta_{max}$ (deg) $N_t$ $N$ ( $R_{int}$ ) $N_o$	$\begin{array}{c} & 7 \\ C_{28}H_{30}{\rm CIIrN_2O_2} \\ 654.2 \\ {\rm Monoclinic} \\ P_{21/c} \ (\#14) \\ 7.5905(7) \\ 21.337(2) \\ 15.560(2) \\ 101.893(2) \\ 2466 \\ 1.762 \\ 4 \\ 5.6 \\ 0.18 \times 0.10 \times 0.08 \\ 0.65 \\ 75 \\ 51205 \\ 12742 \ (0.048) \\ 9804 \\ \end{array}$		$\begin{array}{r} 8 \\ \hline C_{34}H_{34}ClN_2O_2Rh \\ 641.0 \\ Monoclinic \\ P\bar{1}(\#2) \\ 8.2875(6) \\ 13.778(1) \\ 14.610(1) \\ 109.429(2) \\ 95.937(2) \\ 106.875(2) \\ 1468 \\ 1.450 \\ 2 \\ 0.71 \\ 0.15 \times 0.09 \times 0.06 \\ 0.92 \\ 75 \\ 27373 \\ 15079 (0.025) \\ 11973 \\ \end{array}$	$\begin{array}{c} 12\\ \hline C_{28}H_{30}BrN_{2}O_{2}Rh\\ 609.4\\ \hline Monoclinic\\ P2_{1/c} (\#14)\\ 7.618(1)\\ 21.329(4)\\ 15.605(3)\\ 101.784(3)\\ 2482\\ 1.630\\ 4\\ 2.3\\ 0.15\times 0.09\times 0.07\\ 0.84\\ 50\\ 17150\\ 4512 (0.054)\\ 3482\\ \end{array}$
formula $M_r$ cryst syst space group a (Å) b (Å) c (Å) $\alpha$ (deg) $\beta$ (deg) $\gamma$ (deg) V (Å <sup>3</sup> ) $D_c$ (g cm <sup>-3</sup> ) Z $\mu$ (mm <sup>-1</sup> ) specimen (mm) $T_{\min/max}$ $2\theta_{max}$ (deg) $N_t$ $N$ ( $R_{int}$ ) $N_o$ R	$\begin{array}{c} & 7 \\ C_{28}H_{30}{\rm CIIrN_2O_2} \\ 654.2 \\ {\rm Monoclinic} \\ P_{21/c} \ (\#14) \\ 7.5905(7) \\ 21.337(2) \\ 15.560(2) \\ 101.893(2) \\ 2466 \\ 1.762 \\ 4 \\ 5.6 \\ 0.18 \times 0.10 \times 0.08 \\ 0.65 \\ 75 \\ 51205 \\ 12742 \ (0.048) \\ 9804 \\ 0.037 \end{array}$		$\begin{array}{r} 8 \\ \hline C_{34}H_{34}ClN_2O_2Rh \\ 641.0 \\ Monoclinic \\ P\bar{1}(\#2) \\ 8.2875(6) \\ 13.778(1) \\ 14.610(1) \\ 109.429(2) \\ 95.937(2) \\ 106.875(2) \\ 1468 \\ 1.450 \\ 2 \\ 0.71 \\ 0.15 \times 0.09 \times 0.06 \\ 0.92 \\ 75 \\ 27373 \\ 15079 (0.025) \\ 11973 \\ 0.043 \\ \end{array}$	$\begin{array}{c} 12\\ \hline C_{28}H_{30}BrN_{2}O_{2}Rh\\ 609.4\\ \hline Monoclinic\\ P2_{1/c} (\#14)\\ 7.618(1)\\ 21.329(4)\\ 15.605(3)\\ 101.784(3)\\ 2482\\ 1.630\\ 4\\ 2.3\\ 0.15\times 0.09\times 0.07\\ 0.84\\ 50\\ 17150\\ 4512 (0.054)\\ 3482\\ 0.038\\ \end{array}$

<sup>a</sup> (x,y,z,U<sub>iso)H</sub> refined. <sup>b</sup> Weak and limited data would support meaningful anisotropic displacement parameter refinement for Rh, Cl only.

displacement parameter forms for the non-hydrogen atoms,  $(x,y,z,U_{iso})_H$  constrained at estimated values. Conventional residuals R and  $R_w$  on |F| at convergence (weights =  $(\sigma^2(F) + 0.0004F^2)^{-1}$ ) are quoted. Neutral atom complex form factors were employed within the Xtal 3.7 program system.<sup>16</sup> Pertinent results are given below and in Tables 1 and 3 and the figures, the latter showing 50% probability amplitude displacement envelopes for the non-hydrogen atoms; the hydrogen atoms have an arbitrary radii of 0.1 Å.

## **Results and Discussion**

The [{ $(\eta^5-C_5Me_5)MCl$ }<sub>2</sub>( $\mu$ -Cl)<sub>2</sub>] (M=Rh, Ir)<sup>17</sup> compounds were reacted at room temperature with stoichiometric amounts of the sodium salt of acylpyrazolone NaQ in toluene to produce [Cp\*M(Q)Cl] derivatives 1-9 (eq 1)

$$[MCp*Cl]_{2}(\mu-Cl)_{2}] + 2QNa \rightarrow [Cp*M(Q)Cl] + 2NaCl$$

$$1-9$$
(1)
1: M = Rh, Q = Q<sup>Me</sup>
2: M = Ir, Q = Q<sup>Me</sup>
3: M = Rh, Q = Q<sup>Et</sup>
4: M = Rh, Q = Q<sup>Piv</sup>
5: M = Ir, Q = Q<sup>Piv</sup>
6: M = Rh, Q = Q<sup>Bn</sup>
7: M = Ir, Q = Q<sup>Bn</sup>
8: M = Rh, Q = Q<sup>S</sup>
9: M = Ir, Q = Q<sup>S</sup>

Slow diffusion of petroleum ether into toluene or dichloromethane solutions of [Cp\*M(Q)Cl] compounds produced, in a number of cases, single crystals suitable for X-ray structure analyses. Complexes 1-9 are air-stable and soluble in chlorinated and other common solvents such as toluene,

<sup>(16)</sup> Hall, S. R., du Boulay, D. J., Olthof-Hazekamp, R., Eds. *The Xtal 3.7 System*; University of Western Australia: Crawley, Australia, 2001.

<sup>(17)</sup> White, C.; Yates, A.; Maitlis, P. M.; Heinekey, D. M. Inorg Synth. 1992, 29, 228–234.

Table 2. Selected Geometries, [Cp\*MQX]<sup>a</sup>

	1	2	4	6	7	8	12	
M/X/Q	Rh/Cl/Q <sup>Me</sup>	Ir/Cl/Q <sup>Me</sup>	Rh/Cl/Q <sup>Piv</sup>	Rh/Cl/Q <sup>Bn</sup>	Ir/Cl/Q <sup>Bn</sup>	Rh/Cl/Q <sup>S</sup>	Rh/Br/Q <sup>Bn</sup>	
distances (Å)								
M-X	2.3996(6)	2.4065(9)	2.378(5)	2.414(1)	2.4058(9)	2.4208(5)	2.5457(6)	
M-O(41)	2.100(2)	2.111(3)	2.13(1)	2.111(3)	2.113(3)	2.126(1)	2.103(3)	
M-O(5)	2.093(2)	2.108(2)	2.11(1)	2.095(3)	2.107(3)	2.122(2)	2.104(3)	
M-C(Cp*)	2.106(2)	2.127(3)	2.01(2)	2.113(4)	2.124(3)	2.125(2)	2.120(4)	
	-2.128(2)	-2.144(3)	-2.17(2)	-2.144(4)	-2.140(4)	-2.139(2)	-2.148(4)	
<m-c(cp*)></m-c(cp*)>	2.119(9)	2.136(6)	2.10(6)	2.131(12)	2.134(6)	2.132(6)	2.125(13)	
M-C(0)	1.740	1.752	1.74	1.752	1.750	1.750	1.752	
			angles (o	leg)				
C(0)-M-X	127.8	129.4	127.5	127.4	128.6	126.6	126.4	
C(0) - M - O(41)	124.3	125.3	126.8	126.6	127.6	126.7	126.5	
C(0) - M - O(5)	128.0	129.2	128.5	126.4	127.8	127.1	126.7	
X-M-O(41)	88.73(4)	86.09(7)	87.8(4)	86.29(7)	84.31(7)	86.94(4)	86.91(8)	
X-M-O(5)	86.54(4)	84.24(7)	86.0(3)	89.34(7)	86.76(7)	89.38(4)	89.95(8)	
O(41)-M-O(5)	88.62(6)	88.2(1)	86.2(5)	87.8(1)	87.05(11)	87.09(5)	87.6(1)	
M - O(41) - C(41)	129.0(1)	129.4(2)	130(1)	128.7(3)	130.0(3)	126.0(1)	129.1(3)	
M-O(5)-C(5)	122.1(1)	122.5(2)	122(1)	121.9(3)	123.0(2)	117.2(1)	121.9(3)	
interplanar dihedral angles (deg)								
$N_2C_3/C_6$	4.64(8)	6.0(1)	4.4(7)	5.7(1)	5.5(1)	24.04(8)	5.3(2)	
$N_2C_3/C_5$	49.60(9)	51.7(1)	55.4(9)	68.9(2)	68.7(1)	89.47(8)	70.1(2)	
			out-of-plane dev	viations (Å)				
$\delta M/C_3N_2$	0.143(4)	0.163(7)	0.22(4)	0.322(8)	0.260(7)	0.882(4)	0.330(9)	
$\delta M/C_5$	1.737(1)	1.747(1)	1.727(2)	1.750(1)	1.747(1)	1.746(1)	1.750(1)	

<sup>*a*</sup> C(0) is the centroid of Cp\*.

Table 3. Selected Ligand Geometries<sup>a</sup>

distances (Å)							
	1	2	6	7	8	12	
N(1)-N(2)	1.390(3)	1.401(4)	1.403(4)	1.400(4)	1.396(2)	1.402(5)	
N(1)-C(5)	1.362(3)	1.362(4)	1.379(5)	1.364(5)	1.368(3)	1.371(6)	
N(1)-C(11)	1.405(3)	1.431(4)	1.422(5)	1.425(5)	1.416(3)	1.423(6)	
N(2)-C(3)	1.305(3)	1.315(5)	1.310(5)	1.311(5)	1.317(3)	1.308(6)	
C(3)-C(4)	1.426(3)	1.430(5)	1.431(5)	1.440(5)	1.430(2)	1.441(6)	
C(4) - C(41)	1.403(3)	1.404(5)	1.417(5)	1.411(5)	1.415(3)	1.408(5)	
C(4) - C(5)	1.418(3)	1.429(5)	1.428(5)	1.424(5)	1.429(2)	1.430(6)	
C(41)-O(41)	1.253(3)	1.267(4)	1.254(5)	1.262(4)	1.265(2)	1.263(5)	
C(5)-O(5)	1.261(3)	1.267(4)	1.265(5)	1.275(4)	1.272(2)	1.267(5)	
O(41)····O(5)	2.929(2)	2.934(6)	2.916(4)	2.906(4)	2.927(2)	2.912(5)	
		an	igles (degrees)				
	1	2	6	7	8	12	
N(2)-N(1)-C(5)	111.9(2)	112.5(3)	111.5(3)	111.0(3)	111.9(2)	111.9(4)	
N(2)-N(1)-C(11)	118.5(2)	117.8(3)	119.0(3)	118.6(3)	118.0(2)	118.1(3)	
C(5) - N(1) - C(11)	129.6(2)	129.7(3)	129.4(3)	130.4(3)	129.6(1)	129.8(3)	
N(1)-N(2)-C(3)	105.9(2)	105.2(3)	106.3(3)	106.4(3)	105.8(2)	105.9(3)	
N(2) - C(3) - C(4)	111.7(2)	112.0(3)	111.4(3)	111.2(3)	111.6(1)	112.0(4)	
N(2) - C(3) - C(31)	118.4(2)	118.3(3)	117.5(3)	118.0(3)	118.3(2)	117.9(4)	
C(4) - C(3) - C(31)	129.9(2)	129.6(3)	131.0(4)	130.3(4)	129.5(2)	130.1(4)	
C(3) - C(4) - C(5)	105.0(2)	104.9(3)	105.6(3)	104.1(3)	105.0(2)	104.6(3)	
C(3) - C(4) - C(41)	130.5(2)	130.8(3)	132.2(3)	132.2(2)	131.5(1)	132.2(4)	
C(5)-C(4)-C(41)	124.6(2)	124.3(3)	121.9(3)	123.4(3)	123.1(1)	122.8(4)	
C(4) - C(41) - O(41)	123.6(2)	123.7(3)	124.9(3)	123.7(1)	123.0(2)	124.2(4)	
C(4) - C(41) - C(42)	121.3(2)	121.8(3)	121.4(3)	122.6(3)	120.1(1)	122.2(4)	
O(41) - C(41) - C(42)	115.1(2)	114.5(3)	113.6(3)	113.7(3)	116.8(2)	113.6(4)	
N(1) - C(5) - C(4)	105.5(2)	105.3(3)	105.0(3)	106.8(3)	105.4(1)	105.6(4)	
N(1) - C(5) - O(5)	122.9(2)	123.1(3)	122.7(3)	122.4(3)	123.5(2)	123.0(4)	

<sup>a</sup> **4** is less precise and is, therefore, omitted.

acetonitrile, or acetone. The moderate yields (55-63%) are often the result of the large solubility of **1**-**9** in the solvents employed during the workup. No evidence of a cyclometalation reaction has been found in the case of the Ir(Cp\*) derivatives. The IR spectra of **1**-**9** show the absence of broad absorptions in the range of 2300-2800 cm<sup>-1</sup>, ascribed to intramolecular  $\nu$ (O-H···O) in the neutral free HQ proligands. In addition, the shift to lower frequencies of the  $\nu$ (C=O) band (at ca. 1600 cm<sup>-1</sup>) is in accordance with the deprotonation of HQ and the subsequent coordination of the heterocycle to the metal in the anionic form. In the far-IR region, several absorptions have been detected in the 480-



M = Rh or Ir R' = CH<sub>3,</sub> C(CH<sub>3</sub>)<sub>3</sub> or C<sub>6</sub>H<sub>5</sub>

Figure 2. Two enantiomers of complexes 1-9.

440 and 290–260  $\text{cm}^{-1}$  ranges. These may be assigned to  $\nu$ (M–O) and  $\nu$ (M–Cl), respectively.<sup>18</sup> The <sup>1</sup>H NMR spectra of compounds 1-9, recorded in CDCl<sub>3</sub>, agree well with the formulas proposed. Thus, the presence of an  $\eta^5$ -Cp\* group is inferred from the observation of a unique signal from the methyl protons that invariably appears in the proximity of 1.65 ppm. Moreover, the Cp\* ring-carbon nuclei resonate at 92 ppm in the <sup>13</sup>C{<sup>1</sup>H} NMR spectrum, exhibiting a coupling of ca. 9 Hz with the <sup>103</sup>Rh nucleus. Resonances from the Q ligand are analogous to those found for other rhodium acylpyrazolonates previously reported, consistent with O,O'-chelation to the metal (see the X-ray single-crystal studies below).13 These organometallic compounds are chiralat-metal, and they can exist as a couple of two enantiomers (Figure 2a). In addition, the geminal methylene protons of the Q-acyl substituent in complexes 3-7 are diastereotopic and produce the expected AB quartets (see Experimental section). For this reason, we have explored the use of the diasterotopic CH<sub>2</sub> protons of bonded QEt, QPiv, and QBn as a probe in coalescence experiments carried out to understand the stability of metal configuration in solution (Figure 2b).

We performed some VT NMR experiments by warming the solution of derivatives **3**, **4**, and **6**, and no change was observed in the CDCl<sub>3</sub> spectra up to 55 °C; the AB quartets were always present. On the other hand, complexes **3**, **4**, and **6** immediately dissociate in the strongly coordinating deuterated solvents DMSO and CD<sub>3</sub>CN which can displace the Q ligand from the metal coordination sphere, totally, or at least partially, upon rupture of one diketonate arm. In fact, in these solvents, quartets are not present both at low and





**10**: S = MeCN, X = NO<sub>3</sub>; **11**: S = H<sub>2</sub>O, X = ClO<sub>4</sub> **Figure 3.** Proposed ionic structure for compounds **10** and **11**.

room temperature. Coalescence studies (also in different solvents) were not possible in the case of the Ir complexes **5** and **7** because decomposition commences at temperatures above 40 °C. Decomposition is also observed in nitromethane or benzene solutions.

The reactions of  $[Cp*Rh(Q^{Me})Cl]$  1 with AgX in notanhydrous MeCN yielded derivatives 10 and 11.

$$[Cp*Rh(Q^{Me})Cl] + AgX \xrightarrow{Solv} [Cp*Rh(Q^{Me})(Solv)]X + AgCl$$
(2)
10: X = NO<sub>3</sub>; Solv = MeCN
11: X = ClO<sub>4</sub>; Solv = H<sub>2</sub>O

They are salt-like, both in solution and in the solid state. The latter assumption is confirmed from their IR spectra, which exhibit bands from noncoordinated nitrate (**10**) and perchlorate groups (**11**). In both cases, the halide exchange is accompanied by coordination of a solvent molecule, consistent with the low tendency of Rh to coordinate NO<sub>3</sub> and ClO<sub>4</sub> groups. A byproduct in the synthesis of compound **11** is [Cp\*Rh(Cl)(H<sub>2</sub>O)<sub>2</sub>]ClO<sub>4</sub>, which we have always found in the mother liquor or in the precipitate, independent of the amount of silver salt employed. The <sup>1</sup>H and <sup>13</sup>C NMR spectra of **10** and **11** exhibit the same pattern found in the spectrum of **1**, suggesting O<sub>2</sub>-chelating bidentate coordination for Q and  $\eta^5$ -coordination for Cp\*, in accordance with the structure proposed in Figure 3.

Attempts to alkylate compounds 1-9 led only to halide exchange, as revealed for example by the reaction of 6 with CH<sub>3</sub>MgBr. This produces the complex  $[Cp*Rh(O^{Bn})Br]$ , 12, where a chloride ligand has been displaced by bromide in the rhodium coordination sphere. It is worth noting that halogen-exchange reactions often require a 10-fold excess of NaX (X = Br or I) and that, after a short time, the reaction mixture reaches equilibrium. In the present case, the reaction is fast, and the chloride displacement by bromide is complete within about 2 min. The spectroscopic features of 12 are similar to those found for the parent compound 6, the only difference being the expected displacement of the band, because of Rh–X, from 260 cm<sup>-1</sup> in **6** to 240 cm<sup>-1</sup> in **12**. Chloride dissociation is also observed in the interactions of derivatives 2, 4, and 6 with  $PPh_3$  yielding complexes [Cp\*Rh(Q)(PPh<sub>3</sub>)]Cl, **13–15**. The displacement of the Cl from the Rh-coordination sphere and the formation of an ionic compound has been confirmed by the disappearance of the IR band for  $\nu$ (Rh–Cl). In no case was the coordination of two PPh<sub>3</sub> groups observed, nor when the reaction was carried out in a large excess of the P donor. In contrast to



Figure 4. Three possible isomers for compounds 13–15.

 Table 4.
 Selected ESI-MS Data (CH<sub>3</sub>CN)

compound or mixture	$[Cp*M(Q)]^+$	$\{[Cp*M(Q)]_2Cl\}^+$	$\{[Cp*M(Br)]_2Cl\}^+$	$(Cp^{*})_{2}M_{2}Br_{3}^{+}$	[Cp*M(PPh <sub>3</sub> )(Q)] <sup>+</sup>	[Cp*MCl(MeCN)] <sup>+</sup>	$(Cp^*)_2M_2Cl_3^+$
<b>1</b> <sup>a</sup>	453 (100)	941 (10)					
1 + RBr	453 (55)		670 (25)	715 (100)			
$2^b$	543 (100)	1121 (10)				404 (70)	
<b>2</b> + RBr	543 (10)		849 (23)	893 (100)			
<b>8</b> <sup>c</sup>	605 (100)	1245 (8)					
<b>9</b> <sup>d</sup>	695 (100)	1425 (5)				404 (70)	
11 <sup>e</sup>						314 (100)	580 (20)
11 + RBr			670 (75)	715 (10)			580 (40)
<b>13</b> <sup>f</sup>	453 (5)				715 (100)		
13 + RBr	453 (5)				715 (100)		
$14^g$					771 (100)		

<sup>*a*</sup> [Cp\*Rh(QMe)Cl]. <sup>*b*</sup> [Cp\*Ir (Q<sup>Me</sup>)Cl]. <sup>*c*</sup> [Cp\*Rh(Q<sup>S</sup>)Cl]. <sup>*d*</sup> [Cp\*Ir(Q<sup>S</sup>)Cl]. <sup>*e*</sup> [Cp\*Rh(Q<sup>Me</sup>)H<sub>2</sub>O]ClO<sub>4</sub>. The most abundant peak in the positive spectrum of **11** is m/z 627 (100) {[Cp\*Rh(Cl)]<sub>2</sub>Br}<sup>+</sup>. In the negative spectrum of **11**, the most abundant peaks are m/z 99 (100) [ClO<sub>4</sub>]<sup>-</sup> and m/z 534 (20) [Rh(Cp)(ClO<sub>4</sub>)<sub>3</sub>]<sup>-</sup>. <sup>*f*</sup> [Cp\*Rh(Q<sup>Me</sup>)(PPh<sub>3</sub>)]Cl. <sup>*s*</sup> [Cp\*Rh(Q<sup>Piv</sup>)(PPh<sub>3</sub>)]Cl.

the situation described above for complexes 1-9, the <sup>1</sup>H and <sup>31</sup>P NMR spectra of compounds 13–15 exhibit signals from the two possible isomers (for instance, doublets  $\delta$  30.71 and 30.44, with a  ${}^{1}J(P-Rh)$  value of ca. 145 Hz can be detected in the  ${}^{31}P{}^{1}H$  NMR of 13). In CDCl<sub>3</sub> solution at room temperature, the equilibrium concentration of isomers is approximately 4:1 for all compounds 13-15. We hypothesize that in solution the breaking of one of the Rh-Odiketonate bonds (likely to be dependent on the steric hindrance of the P donor) and the coordination of solvent molecules or of the same chloride ions, occurs with the formation of two different species, for example, two of those reported in Figure 4. This seems to be supported by the IR spectra of 13-15 in which the C=O stretching frequencies have different values from those reported for the corresponding [Cp\*Rh(Q)(Cl] containing a bidentate Q ligand. However, we cannot exclude the possibility of a complete dissociation of 13–15 in solution and formation, for example, of [Cp\*Rh(PPh<sub>3</sub>)(Solv)(Cl] species.

Table 4 summarizes the ESI MS data for selected derivatives **1**, **2**, **8**, **9**, **11**, **13**, and **14** and also for mixtures containing derivative **1** or **8** and AgClO<sub>4</sub>, PR<sub>3</sub>, benzylbromide, or Grignard reagents. The m/z values of prominent peaks corresponding to rhodium or iridium cations are given together with formula assignments. It is to point out that, in the case of the halide derivatives **1**, **2**, **8**, and **9**, the most abundant signal is that from the [Cp\*M(Q)]<sup>+</sup> cation. In the ESI spectra of **1**, **2**, **8**, and **9**, a signal ascribed to a dinuclear species generated by the loss of one halide group wherein two cyclopentadienyl-metal moieties are likely bridged by an halide or a pyrazolonate ligand is also present. When an equimolar quantity or an excess of benzyl bromide or Grignard reagent, RMgX (R = Et, Bu<sup>n</sup>; X = Br), was added to a MeCN solution of **1** or **8**, signals corresponding to the

 $[(Cp^*)_2Rh_2Br_3]^+$  and  $[(Cp^*)_2Rh_2Br_2Cl]^+$  species were immediately identified. In the case of PR<sub>3</sub> derivatives **13–14**, the signals from the ionic species  $[Cp^*Rh(PR_3)(Q)]^+$  were always the most abundant. No change was observed in the ESI spectra when benzyl bromide was added to a solution containing derivative **13**, suggesting a high stability for these species in solution.

A different behavior has been found in the positive spectrum of derivative **11**, the most abundant species detected in solution being  $[Cp*Rh(Cl)]^+$ ,  $[(Cp*)_2Rh_2(Cl)_3]^+$ , and  $[(Cp*)_2Rh_2(Cl)_2(ClO_4)]^+$ . The anionic ligand Q<sup>-</sup> is present, unassociated, in the negative spectrum together with signals from the  $ClO_4^-$  and  $[Cp*Rh(ClO_4)_3]^-$  anions. This suggests a high instability of compound **11** in MeCN solution where it immediately dissociates yielding a plethora of species, which also contain coordinated perchlorate groups, and confirming the possibility of displacing anionic ligands, such as the pyrazolonate donors, from the metal coordination sphere with solvent molecules, such as MeCN or H<sub>2</sub>O.

Finally, when benzyl bromide was added to a solution of **11** in MeCN, the ESI-MS spectrum exhibits, in the positive mode, a number of peaks from dinuclear species containing bridging-halide groups:  $[(Cp^*)_2Rh_2(Cl)_3]^+$ ,  $[(Cp^*)_2Rh_2(Cl)_2Br_3]^+$ ,  $[(Cp^*)_2Rh_2(Cl)_2Br_3]^+$ , and  $[(Cp^*)_2Rh_2(Br_3)^3]^+$ . In the positive spectra, no signals containing the  $\beta$ -diketonate donor, the most abundant species found in the negative ESI spectra, have been detected.

The result of the "low-temperature" single-crystal X-ray structure determinations are consistent with the above formulations in terms of stoichiometry and connectivity; in all cases, the species take the form [Cp\*M(Q)X] with one mononuclear neutral molecule, devoid of crystallographic symmetry and no intrinsic molecular symmetry, comprising the asymmetric unit of each structure (Figure 5); all



Figure 5. Projections of individual molecules of 1, 4, 6, and 8 (as representative) normal to their ligand planes.



Figure 6. Racemic mixture found in the crystals of 1, 2, 6, 7, 8, and 12.

compounds crystallize in centrosymmetric space groups (i.e., the specimens were racemic) (Figure 6).<sup>19</sup> Isomorphous arrays are found for M = Rh, Ir; X = Cl (1, 2, 6, and 7) and M = Rh, X = Br (12) permitting the comparison of different metal atoms in similar other-atom environments and of different halides in otherwise similar systems. In all such systems, except 12, where X = Br, and 4, where the precision is limited, the metal-donor atom distances are remarkably invariant (Table 2); the angles are slightly more diverse, but not so much as to suggest the presence of any unusual or unexpected trends, and although the oxygen donors are of two rather different types, their M-O distances are similar, although the M–O–C angles differ between O(41 and 51). Some differences are evident for **8**, most notably in the N<sub>2</sub>C<sub>3</sub>/C<sub>5</sub> interplanar dihedral angle, perhaps dependent on some steric effect derivative of the bulk of the ligand substituent, but also in respect of the angle, at O(5), where the effect may be electronic, contingent on both the substituent and the change in torsion of the nearly phenyl group. An inspection of the distances and angles within the conjugated section of the aromatic ligand across the series shows remarkable insensitivity in this dimension (Table 3). Not surprisingly, crystal packings appear to be primarily determined by inversion-related parallel dispositions of the planar components.

#### Conclusions

Rh(III) diketonate complexes of formula [Cp\*M(Q)Cl] (M = Rh or Ir, Cp\* = pentamethylcyclopentadienyl, HQ = 1-phenyl-3-methyl-4R(C=O)-pyrazol-5-one) can be easily synthesized by reaction of [Cp\*MCl<sub>2</sub>]<sub>2</sub> with the adequate sodium salt NaQ. [Cp\*M(Q)Cl] complexes exist as enantiomers, both in the solid state and in solution, the metal being a center of chirality. It is noteworthy that [Cp\*M(Q)Cl] complexes are stable in the solid state and in the atmosphere

<sup>(19)</sup> Consiglio, G.; Morandini, F. Chem. Rev. 1987, 87, 761-778.

for a long time, and they are also stable in weak polar solvents (such as CHCl<sub>3</sub>) and up to 55 °C. No signal from the coalescence of the geminal methylene-proton quartets in derivatives **3**–**7** has been found. This is a probe of the lack of interconversion and of the stability of both conformations in solution. These compounds are resistant to carbanionic attack by RMgX or RX species. Br<sup>-</sup> is however able to displace the Cl<sup>-</sup> from the Rh center. The Cl<sup>-</sup> can be also displaced by solvent molecules, as in the exchange reaction of [Cp\*M(Q)Cl] with AgX (X = NO<sub>3</sub>, ClO<sub>4</sub>), in which ionic species [Cp\*M(Q)(MeCN)]X or [Cp\*M(Q)(H<sub>2</sub>O)]X are obtained. Finally P donors, such as PPh<sub>3</sub>, are able to coordinate [Cp\*Rh(Q)Cl], easily displacing Cl<sup>-</sup> from the metal coordination sphere and yielding ionic chiral-at-metal

complexes  $[Cp*Rh(Q)(PPh_3)]Cl$ . Also, the acylpyrazolonate ligand, Q, can be expelled from the metal coordination sphere, as demonstrated by ESI-MS studies and by the formation of byproducts such as  $[Cp*Rh(Cl)(H_2O)_2]ClO_4$  in the reaction of [Cp\*Rh(Q)Cl] with an excess AgClO<sub>4</sub>.

Acknowledgment. We would like to thank Ernesto Carmona for helpful discussion and the University of Camerino INTAS Project 00469, Cooperlink, and Fondazione CARIMA.

**Supporting Information Available:** Full crystallographic data in CIF format. This material is available free of charge via the Internet at http://pubs.acs.org.

IC050985R